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ABSTRACT
Ovarian cancer is the fifth leading cause of cancer death among women in
United States and has an alarming 1.4% (1 in 71) lifetime risk. The lack of overt
symptoms and the absence of a reliable screening test to detect ovarian cancer result in
over 70% of women being diagnosed after the disease has spread beyond the ovary
resulting in a poor prognosis. A key characteristic of ovarian cancer is the ability of tumor
cells to evade apoptosis, or programmed cell death contributing to the limitless
replicative potential, which is a hallmark of all carcinogenesis. There is conclusive
evidence that levels of bcl-2 are elevated in ovarian cancer patients‟ indication that this
protein is an ovarian cancer biomarker. The overall goal of this thesis is to functionalize
a substrate for specific, sensitive and cost-effective bcl-2 capture. This surface will
ultimately be incorporated into an acoustic wave-based diagnostic device for worldwide
point-of-care (POC) ovarian cancer detection.
This research looks to assess the capture of this analyte protein on a series of
bioconjugated surfaces. For the research to be diagnostically applicable, certain factors
reveal themselves as more important than others. Since the surface-bound capture
antibody must recognize the bcl-2 protein, it is vital to ensure upright orientation of this
specific antibody with high affinity for the analyte. Furthermore once integrated with a
nanosensor, the surface will sense a change in the mass on the surface, which requires
that the surface is highly resistant to non-specific binding. Bioconjugation techniques
were employed to initiate self-assembled monolayers (SAM) of silanes, immobilize
antibodies (via amine-crosslinking or direct adsorption of protein A/G) and disperse
polyethylene glycol (PEG) reagents to reduce non-specific binding on the glass
vi

substrates. 3-aminopropyltrimethoxysilane (3-APTMS) and chlorodimethyloctylsilane
(ODMS) were deposited on the surface to create initial hydrophilic and hydrophobic
properties on which molecular self-assembly could occur. Testing a variety of
assemblies with and without the presence of silanes, amine-crosslinking and PEGylation
reagents, the substrate displaying the highest efficacy of bcl-2 capture was revealed.
These various surfaces were assessed through contact angle and a novel sandwich
enzyme linked immunosorbent assay (ELISA) for sensitivity and specificity of bcl-2
standard capture.
The consistently low background and facile assembly of the ODMS based
substrate with direct adsorption of protein A/G and the PEGylation reagent, Pluronic,
was deemed the „best‟ functionalized surface for non-specific recruitment of the bcl-2
protein. The substrate also consistently displayed low signal-to-noise ratio which was of
extreme importance in this research to guarantee the prevention of false-positive results
when detecting nascent carcinogenic behavior. Elucidation of this substrate assembly is
the first step towards the long term objective of this thesis, which is to construct a costeffective early ovarian cancer detection device which can be implemented at the pointof-care to those who need it the most. This is ultimately expected to dramatically
improve health outcomes for females worldwide.
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CHAPTER 1: INTRODUCTION
1.1

Motivation for Research
With the rapid advances in proteomic characterization and micro-technologies,

diagnostic techniques have quickly become a catalyst for progression in long term health
strategy, preventative medicine and providing timely care to patients in developed
regions of the world. However the technological capabilities in high-resource settings are
far superior to low-resource settings. It is because of this that the vast majority of deaths
that occur annually from major infectious diseases occur in under-privileged regions of
the world (1). Nevertheless, a solution lies in development of point-of-care (POC)
diagnostic tests which can be easily and efficiently implemented in low resource settings
improving health and general well-being of the world. The ability to produce rapid results
visually, lack of sophistication in operation and low-cost in production: allow POC
diagnostics to be implemented with an extremely high efficacy in high and low resource
settings alike. Thus, POC diagnostic can results in a decrease of the burden of disease
due to infection around the world. Infectious diseases which plague low-resource
settings (acute respiratory infections, malaria, and tuberculosis) often display disease
progression through the generation of biological changes in various ways such as
upkeep of antigens, proteins or antibodies. There is low motivation in regions where the
burden of death is not as high for infectious disease; both intuitively as well as
financially, for initiatives in POC test development. However if the versatility of POC
diagnostics could be applied to detect specific carcinogenic pathways and thus onset of
tumor growth, it would greatly benefit humanity all around the globe. The objective of this
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thesis is to quantify the specificity and selectivity of selected bioconjugated surfaces to a
known ovarian cancer biomarker, the anti-apoptotic bcl-2 protein. The surface with
highest efficacy can then be integrated with a novel nanosensor to create a POC
diagnostic device for worldwide detection of stage I and stage II ovarian cancer.
Ovarian cancer is the fifth leading cause of death among women in United
States and the disease has 1.4% (1 in 71) lifetime risk. Patients with ovarian cancer
have a short median survival time after diagnosis, as the 5-year survival rate being less
than 40%. Early stage ovarian cancer represents an important target for screening
mediums to detect, since the cancer is lethal in most late stage cases. The lack of
explicit symptoms and the absence of a reliable screening test to detect ovarian cancer
results in over 70% of women being diagnosed after the disease has spread beyond the
ovary, when it is too late (2). Currently, the only standardized screening procedures for
ovarian cancer are pelvic examinations, ultrasounds and blood levels of CA-125 or
cancer-antigen 125. However each method has significant limitations. Pelvic
examinations are typically limited to the detection of advanced stages, which is thus of
no consequence towards improving overall prognosis of the disease. Similarly,
ultrasounds are not only incapable to distinguish between benign and malignant disease
but are also subject to variation in interpretations among sonographers (3). Although
CA-125 levels are useful to monitor ovarian cancer progression, they can also be
elevated due to other disorders including benign gynecological disease and hepatic
disease preventing accurate and conclusive identification of early ovarian
carcinogenesis (4). While other screening modalities, including pap-smears for cervical
cancer and mammography for breast cancer detection, respectively, have improved
early detection and survival associated with those tumor types, no true screening exists
for ovarian cancer. The absence of reliable screening methods to detect early ovarian
cancer contributes to the overall poor prognosis of the disease (5). Therefore, this
2

research addresses the need for a reliable, simple, and economic testing platform to
detect ovarian cancer. This master‟s thesis will focus around the elucidation of an elite
bioconjugated surface to specifically and sensitively capture a known biomarker of
ovarian cancer, bcl-2. These results can then be integrated with a novel, inexpensive
nanosensor to quantify the capture creating a POC diagnostic device essentially
enabling worldwide early recognition of ovarian cancer.
This research is predicated upon the use of the bcl-2 protein which can be
considered a biomarker, or biological indicator corresponding to the onset of ovarian
cancer. The apoptosis-regulating family of bcl-2-like proteins contain roughly 25
members and is named for the central anti-apoptotic bcl-2 protein. A great deal of
research over the past two decades has indicated that bcl-2 is overexpressed in a large
number of tumor growths. In 2008, the novel work of Dr. Patricia Kruk at the University
of South Florida revealed that elevated levels of bcl-2 were present in urine from patients
with early as well as late stage ovarian cancer (6). Utilizing these findings, the novelty of
this project lies in being the first of its kind to detect the onset of ovarian cancer via
elucidation of a novel, facile and economical surface functionalization technique capable
of efficient bcl-2 capture. The functionalization approach investigated will focus on
oxygen plasma treatment, silanization, efficient antibody immobilization and
maintenance of non-fouling surface reagents to render self-assembled complexes with
various properties. Subsequently, these test assemblies will be tested by novel
sandwich ELISA technique to arrive at the most suitable substrate for sensitive and
specific bcl-2 capture.

3

1.2

Significance of Research in Ovarian Cancer Diagnostics
Advancements in proteomics and nanotechnology have led to biosensors having

also evolved greatly in sophistication over the past couple decades. The imperative
function of a biosensor is to detect and quantify an analyte, which is the bcl-2 protein in
this research. This biosensor consists of two primary parts: an inorganic platform
capable of analyte recruitment and a nanosensor for concentration quantification. A
nanosensor or transducer can employ a wide variety of principles of detection. For
nanoscale detection an ideal transducer would possess a high electromechanical
coupling coefficient along with low mechanical impedance. Current state of the art
biosensors employ piezoelectric detection techniques and since this technology has
been studied extensively, the behavior and limitations are well understood (7). The
mechanical impedance of the piezoelectric transducers is very high compared to that
needed to measure nanoscale mass loadings. Since the bandwidth of high impedance
piezoelectric materials are very limited, the overall detection sensitivity of piezoelectric
transducers are limited preventing suitable identification parameters. As seen in figure
1.1, the qualities of typical piezoelectric devices possess restrictions on reliable mass
quantification. To overcome the aforementioned limitations there have recently been
findings in an ultrasonic capacitance detection method to identify mass loading change
generated by analyte adhesion on the surface. Work has been published on capacitive
micromachined ultrasonic transducers (CMUTs) design for high bandwidth operation and
electromechanical coupling coefficients for improved transmit and receive performance.
CMUTs also offer additional advantages in ease of manufacturing, stability, low cost,
high yield, and reliability (8, 9)

4

Figure 1.1 Diagnostic Performance of Various Transducers. (7)

The self-assembly that will functionalize the surface with the highest efficacy measured
by bcl-2 capture can therefore be easily integrated with a variety of biosensors enabling
detection worldwide. In order to validate the research it must be certain that a proper
diagnostic device can be created. To do this, first and foremost, the criteria and
specifications of a diagnostic device must be recognized.
The World Health Organization: Sexually Transmitted Diseases Diagnostics
Initiative have coined the term „ASSURED test‟ to describe the ideal characteristics of a
POC diagnostic test (10), seen below. To be deemed an ideal diagnostic device the
operation must be affordable by those at risk of infection, highly sensitive and specific,
have few false-negative as well as false-positive results requiring minimum training and
be performed without any expensive equipment., as seen in figure 1.2 on the next page.
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• Affordable by those at risk of infection
• Sensitive
• Specific
• User-friendly
• Rapid and Robust
• Equipment-free
• Deliverable to those who need it
Figure 1.2 Characterization of the Ideal Diagnostic Test.

This promising research presented in this thesis is the first step in designing a
diagnostic testing platform for urinary bcl-2 level quantification that will provide impetus
towards developments of a new, accurate, safe and simple way of early ovarian cancer
detection. This would undoubtedly result in recognition and treatment of thousands of
previously undiagnosed cases of ovarian cancer. This thesis can result in long term
beneficial impact on cost-effective early ovarian cancer detection at the POC, which can
significantly improve our lives today and the health of our future generations. The
proposed diagnostic device would also satisfy the benchmarks of an ASSURED test:


Affordability: Currently employed proteomic diagnostic techniques are extremely
pricey as each CA-125 enzyme linked immunosorbant assay (ELISA) test kit
costs over $300 ($10 per specimen) and each bcl-2 ELISA test kit costs over
$500 (approximately 18 per specimen) (6). From a standard 16 inch
(approximately 41 cm) diameter silicon wafer, over 4000 nanosensors can be
fabricated. The resulting cost of each nanosensor is less than $1 (8). Once the
surface assembly showing the most diagnostic promise is identified, a large
number of substrates can be functionalized at low costs.
6



Specificity/Sensitivity: The functionalized surface will be classified as a nonfouling surface ensuring that nonspecific binding does not occur, eliminating the
chance for false-positive results. It has been experimentally verified that massloaded nanosensors sensitivity can detect in the order of 0.15 pg/ml truly enabling
early ovarian cancer detection once a novel, facile functionalization technique
can be established (7-9).



User-Friendly: The test would not necessitate the need for trained personnel for
operation. The simple procedure would employ female urine similar to that of the
common pregnancy test and would engender fast, reliable results.



Rapid/Robust: Since only urine is necessary for operation, the need for
refrigeration and specimen storage is eliminated. Also, the nanosensor would
give results instantaneously of a bcl-2 protein from a battery supply. Typically a
standard 1.5 volt battery can supply the energy needed for mass quantification
sensors. Because of the nanoscale realm of the measurements, a large number
of readings can be executed without battery replacement (7).



Equipment Free: A fully-integrated bio-functionalized nanosensor device would
remove the need for any additional equipment for testing besides urine.



Delivery: Since the device would be disposable and conveniently small, it can be
deliverable to those who need it the most. Thus, because of the ease of
transportation of the POC device, a large number of tests can be implemented at
virtually any location.

7

1.3

Utilization of Biomarkers to Uncover Carcinogenic Pathways
Through a complex signal transduction cascade: lymphocytes or white blood

cells maintain homeostasis by surveying a range of antigens inside the body. Upon
detection of an invader antigen, secretion of antibodies to maximally eliminate the
pathogen occurs. Each lymphocyte or B-cell (beta cell) has a unique receptor on its
surface that will capture specific antigens and thereby monitor any irregularities. The
secretion of antibodies to counter these pathogens is a staple of the immune response
whose responsibilities include pathogen and toxic neutralization, innate immunity,
recruitment to upregulate phagocytosis and other cellular purification processes (11).
Cancer and the widespread cellular pandemonium that it causes on affected patients‟
immune response cannot yet be treated as it is not fully comprehended. If we target
various specific deficient or disproportionate cellular-indicator proteins whose
functionality is tampered with by carcinogenic signal transductions, discrete cancers can
be traced at an increasingly earlier timeframe therefore ensuring much more positive
prognosis for patients. This approach bodes well for the future to detect carcinogenesis
as itnot only allows for a great deal of novel techniques but also employs numerous
biomarkers to be elucidated for different types of cancer.
Biomarkers can be understood as an indicator of a biological state and thus can
be the key to detect early stage diseases. This allow for immediate treatment and thus
greatly improve patient prognosis, by understanding some of the biological mechanisms
employed by the disease to override the immune system. There is no disease where the
elucidation of impaired signal pathways is more needed than cancer. There has been a
great deal of biomarkers uncovered in a number of cancers; bcl-2 being the most recent
for ovarian cancer. In 2004, researchers from the department of Medicine and Center for
Cancer Research at the University of Salamanca in Spain quantitatively demonstrated
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elevated levels of bcl-2 expression in a variety of B-cell malignancies: proliferative
neoplastic B-cells malignancies, B-cell acute lymphoblastic leukemia, B-cell
chroniclymphomatic leukemia, diffuse large B-cell lymphoma and multiple myeloma (12).
In 2008, Dr. Patricia Kruk and her colleagues at the Cellular and Molecular Biology
department at the University of South Florida conclusively revealed that urinary levels of
bcl-2 are elevated in ovarian cancer patients (6). Urinary levels of bcl-2, as seen in
figure 1.3 were found in the study to be: 0.59 ng/ml healthy patients, 2.60 ng/ml early stage
and 3.58 ng/ml late stage ovarian cancer (6). Further information regarding bcl-2 as an
ovarian cancer biomarker is presented in chapter 2.4. This thesis aims to evaluate the
capture of the apoptosis regulator protein, bcl-2, on functionalized surface with maximum
specificity and efficacy in hopes to detect ovarian cancer. This groundbreaking research
is the first of its kind to implement a novel assay to detect concentrations of an ovarian
cancer biomarker as an analyte.

Figure 1.3 Bcl-2 Levels Elevated in Ovarian Cancer Patients. (6)

9

1.4

Content of Thesis
Chapter 2 provides detailed information on:


Clinical needs for emerging testing technologies such as POC diagnostics



Novel proteomic methods to reveal biomarkers.



Influence of the Bcl-2 family proteins on cellular survival.



Overview of project.
Chapter 3 provides a comprehensive look into:



Bioconjugation techniques for reagent functionalization on self-assembled
monolayers (SAM) for assays targeting immunoglobulins.



Silanization techniques: 3-Aminoproplytrimethoxysilane (3-APTMS) and
Chlorodimethyoctylsilane (ODMS).



Crosslinking Reagents and protein A/G for immobilization of target antibodies.



Poly (ethylene-glycol) reagents to maintain non-fouling surfaces: MS(PEG)4,
BS(PEG)5 and Pluronic.
Chapter 4 discusses:



Novel ELISA technique used.



Interpreting ELISA readings.



Selection of functionalized surface displaying the maximum bcl-2 analyte
selectivity and specificity.



Serial dilution of bcl-2 protein.
Chapter 5 provides a brief synopsis of the research and the future considerations

needed.
Appendix A and B provide a review of POC tests towards primary infectious
diseases in low-resource settings and proteomic techniques, respectively. Appendix C
contains contact angle measurements and appendix D contains selected ELISA results.
10

CHAPTER 2: CANCER BIOMARKERS IN POINT-OF-CARE DIAGNOSTICS
2.1

Impact of POC Testing on Infectious Disease Detection
Point-of-care (POC) tests can be defined as laboratory tests which are intended

for the purpose to be used directly at the site of patient care resulting in quicker delivery
of results, thus inducing faster clinical decisions. It is because of this that POC tests are
highly advantageous towards the management of infectious diseases. As a result of the
undeniable benefits of POC testing it has quickly become an indispensable part of
intensive-care units, emergency rooms, laboratories of hospital, physicians‟ offices,
outpatient clinics and recently even patients‟ homes. Such tests have become the
fundamental of care for critically ill-patients allowing for evaluation of critical parameters
such as blood or glycaemic control at the patients‟ bedside (13). Therefore, immediate
identification of a disease state allows the use of adequate pragmatic therapy, which has
been shown to improve the outcome in critically ill patients. In the last 15 years, the
availability and use of POC tests have greatly increased and can be found in use all
around the world. Novel engineering of POC testing platforms have resulted in a
significant proportion of laboratory testing currently being conducted at the point of care.
In the setting of infectious diseases, most existing POC tests consist of immunoassays,
namely agglutination, immunochromatographic and immunofiltration tests (14).
Ideal POC tests need to rely on easily accessible mediums such as urine, blood,
saliva, or nasopharyngeal (throat) swabs. Although the use of these tests does not
require laboratory expertise to conduct, inevitably performance is clearly linked to the
experience of the operator and this factor can influence the overall validity of the results.
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POC tests are usually assessed in comparison with standard microbiological
procedures, sometimes being performed at the same time consequently allowing for the
POC test to be quantifiably measured. As biomedical engineers, developing
technologies in response to the needs of the always transforming world‟s medical
community is a primary way to have a large impact on society in a highly benevolent
manner. In this way the most basic medium for disease detection techniques lie in POC
diagnostics (15).

2.1.1 Impact of POC Testing in Low-Resource Settings
The „global burden‟ of disease is a comprehensive regional and global
assessment of the mortality and disability caused by various diseases. As a means of
comparing the burdens of mortality produced by distinctive diseases, the World Health
Organization (WHO), has proposed the use of DALYs or disability-adjusted life-years as
a quantifiable measure of the severity of a disease, as seen in figure 2.1 (16). Not
surprisingly, the majority of deaths that are caused by infectious diseases occur in third
world countries or low-resource settings. As a matter of fact, out of all the deaths
annually from major infectious diseases (HIV, malaria, tuberculosis and acute respitory
illnesses), approximately 95% of the deaths occur in low-resource settings with Africa
shouldering the largest burden (17). Given that rapid POC diagnostic tests are
inexpensive to produce, simple to perform, produce prompt visual readouts and often do
not necessitate equipment, the potential value for infectious disease POC tests in lowresource settings are greater than in developed regions. This conjecture is widely
agreed upon and because of this, diagnostic technology advancement has not garnered
the same financial backing and devoted resources as other sectors of bioengineering
such as drug delivery and vaccine development (18). It is not until recently that POC
diagnostics have looked to be applied for detecting the onset of carcinogenesis.
12

Figure 2.1 Burden of Diseases Worldwide. (18)
(DALYs lost to a. genre of disease b. specific disease)
13

Table 2.1 Staffing Constraints in Low-Resource Settings.

There are a great deal of reasons that infectious disease plague low resource
settings. Staffing constraints is one (as seen in table 2.1), as a lack of quality training
leads to deficient health care providers. Partial immunity also becomes a problem, as in
high-disease endemic regions where locals may have elevated levels of a „latent‟
biomarker, otherwise effective diagnostic tests can become inconclusive. Language is
also an enormous confounder in deciphering information. In addition there are often
local, unique terminologies to describe specific disease conditions which may not be
understood by outsiders. Patients implementation of alternative medicine for certain
symptoms, can locally impact the timeliness of patient presentation to a health care
facility. Overall neglect is alarming as well, in one study conducted in Malawi that
evaluated the delivery of tuberculosis (TB) samples to a central reference laboratory
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found that only 40% of the test samples collected were successfully transported (19,20).
The internal infrastructure of the health care is much to be desired in under-privaledged
localities as well. Not only are government obtained supplies of sub-par quality, but
routinely the procurement of supplies is unstructured and inconsistant. Coupled with the
fact that there are no external quality assessments put into practice, diagnostic tests
consistantly underperform. Besides these concerns, specimen collection and processing
as well as instrumentation also contribute to the diminished efficacy of diagnostic tests in
low resource settings (21).
The characteristics of an appropriate diagnostic tests that could effectively be
implemented worldwide according the WHO as mentioned in section 1.2, can be
explained by the mnemonic ASSURED. A test passing the criteria of ASSURED can be
considered a POC diagnostic, which would allow for circumvention of a great deal of
regional limitations described before. Since current diagnostic methods do not reliably
and accurately detect ovarian cancer, there is a tremendous need to develop a safe,
cost effective, reliable, preferably non-invasive method to detect early stages of the
disease. Ultimately goal of this thesis is to develop and medically evaluate a testing
platform for a simple, disposable, tiny (sensor component is smaller than human hair or
sand particle), low cost (<$1), battery operated (>1 million hours operation with an offthe-shelf AAA battery), ultra-sensitive (~0.15 pg/ml) ovarian cancer diagnostic device for
early detection at the point of care.

2.1.2 Impact of POC Testing in High-Resource Settings
Perhaps the most overlooked benefit that POC diagnostic tests offer developed
regions of the world is that of elimination of the threat of drug resistance. Drug resistance
has become a major concern in the management of malaria, TB, HIV and other bacterial
infections, comprimising well-being of future generations. Physicians all around the
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world may be guilty for the overuse of antibiotics before the definitive identification of the
disease. Passive resistance that is acquired over time, threatens the solution of cheap
drugs for treatment of various diseases in the developing and developed countries of the
world. POC testing might assist in limiting the overuse of antibiotics as well as
prevention of therapeutic drug resistance (22). Therefore further execution of POC
testing worldwide would encourage prescription of drugs only once the disease state has
been identified. Consequently POC diagnostics can be considered a preventative health
measure, helping to eradicate drug resistance around the world. If a specific biomarkers
can be corresponded to carcinogenesis or any other disease pathology, then novel
techniques of specific and sensitive capture of the targeted cancer-marker can be made
by means of a POC diagnostic.

2.2

Carcinogenic Pathways for Biomarker Discovery
Cancer research has long been one of the most funded clinical endeavors and as

a result, a great deal of strides have been made in understanding carcinogenesis. That
being said the sequential, parallel, and interconnected overrides on cellular function that
cancer imposes, is still something that engineers, scientist and doctors cannot fully
explain (10). Recently, there have been many initiatives in the biomedical world to
detect cancer at an incipient stage so as to terminate its‟ advancement; thereby reducing
the mortality rate associated with the disease. There are more than 100 distinctive types
of cancers and further range of tumors that can be found in specific organs. Affected
cancer succeeds in manifesting physiologic changes due to superseding the defensive
mechanisms in the body. Though cancer is present in many names and resides in a
multitide of bodily locations, it has been proposed that all cancer cell genotypes exhibit

16

six distinct modifications (as seen in Figure 2.2), that collectively induce malignant tumor
growth. Understanding the alterations that carcinogenic genes perform on our
„molecular signature‟ will help in exposing discrete analyte biomolecules that can be
markers for the onset of specific carcinogenesis (23). Figure 2.2 (described in detail
below), defines the essential traits that are present, to some extent, in all carcinogenic
behavior.

Figure 2.2 Essential Traits of Carcinogenisis. (23)

2.2.1 Sustained Angiogenesis
Angiogenesis is the development of new blood vessels in nascent tissue.
Proliferating cells do not have the tendency to encourage blood vessels growth and as a
result, angiogenesis is a trait that must be developed. As a result, carefully coordinated
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positive and negative signals from the body which induce specific growth, called growth
factors or GF, engender angiogenesis. Angiogenic-promoting GF include vascular
endothelial growth factors (VEGF) and fibroblast growth factors (FGF1 and FGF2)
whereas angiogenic-inhibitors include thrombospondin-1 and β-interferon. It is believed
that specialized oncogenes (cancer genes), serve as a catalysts to promote and sustain
angiogenic activity from otherwise vascular acquiescence. Tumors appear to
accomplish this by gene transcription. The combination of increased expression of
VEGF and FGF1 and down regulation of thrombospondin-1 and β-interferon is a
technique employed by oncogenes to sustain angiogenesis in affected cells. Because of
the complexities in transcriptional control of GFs, the mechanisms dictating shifts in
angiogenic balances remain unknown (24, 25).

2.2.2 Tissue Invasion and Metastasis
During the progression of most types of cancer, primary malignant cells spawn
clones which then invade adjacent tissues. This process eventually disrupts the
indispensable homeostasis within the body, resulting in cell and tissue death. As a
matter of fact, the distant site of tumor cells (metastasis) causes 90% of human cancer
deaths (23). Several cell-cell adhesion molecules (CAM) and integrins are are
responsible for transducing proteins involved in tethering for cellular motility. It is an
exceedingly complex process which entails multiple signal transductions at diverse
locations. As a result, pin-pointing biological effects of specific CAMs and integrin
interactions is difficult because they are convoluted by the large amount of ligandreceptors groupings, resulting in a large array of combinatorial expression potential. Ecadherin, present in epethelial cells, is the most widely observed modification to
standard cell-to-environment interactions from carcinogenesis. E-cadherin bridges
adjoin neighboring cells and allow transmission of anti-growth and other signals.
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Successful supression of E-cadherin also muffles the anti-growth signals allowing
metastasis to eventually transpire. This fact is corroborated from cell culture evidence:
E-cadherin serves as a supressor of invasion and metastasis and its operative
elimination represents a key step in carcinogenesis (26, 27).

2.2.3 Insensitivity to Anti-Growth Signals
Anti-growth signals are tranduced to block proliferation in two techniques. Cells
may be forced to their quiescent state (indicated as G0), excluding them from
proliferative activity or they can be induced to abandon the proliferative potential and
placed in a post-mitotic state: acquiring differentiaton-specific traits. In the early stages
of cellular growth (G1 phase), cells monitor their environment through sensed growth
signals and decide whether to proliferate, be dormant, or enter a postmitotic stage. At
the molecular level the anti-proliferative triggering signals are initiated by the
retinoblastoma protein (pRb). In cervical carcinoma the pRb function is eradicated by
viral oncogenes, such as the E7 oncoprotein of the human papillomavirus. The integrin
TGFβ also becomes disfunctional because of specific cancer cells. Due to either
downregulation of TGFβ receptors or mutation of the adhesion site, the phosphorylation
that impedes the pRb function is prevented. Thus, the cell is suspended and is unable to
contiue to the following growth stage where DNA replication and differentiaion occurs.
Disruption of the vital anti-growth pRb circuit contributes towards cancer‟s notorius
uninhibited spread (23, 28).

2.2.4 Self-Sufficiency in Growth Signals
Coupled with the ability to disregard anti-growth signals, the cability of tumor cells
to generate their own growth signals (GS) allows cancer cells complete immunity from
the growth signaling defense-mechanisms that are a part of our immune system.
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Sufficient laboratory evidence has proven that oncogenes attack by mimiking normal
growth signaling in one way or the other. Normal cells require mitogenic GS to serve as
the catalyst modifying them to a proliferative state. These GS are transduced by
complex transmembrane receptor-ligand interactions from GFs, extracellular matrix and
cell-cell adhesions. In culture, oncogenes generate many of their own GS and in doing
so reduce the dependency on stimulation from the normal micro-environment. The cell
surface receptors that are responsible for growth-stimulation are also deregulated by
carcinogenesis. GF receptors tend to possess tyrosine kinase activities in their
cytoplasmic region and are overexpressed by many cancer cells. As a result, customary
populations of GFs can lead to hyper-activity of the cells proliferative capabilities as a
result of the amplified GF receptors on the oncogenes. Moreover, the epidermal GF
receptor EGF-R is overexpressed in stomach, brain and breast tumors while HER2
recepetor is upregulated in stomach and mammary cancers (23,29).

2.2.5 Avoiding Apoptosis
The capability of tumor cell populations to increase is influenced by not only cell
proliferation, but by the circumvention of cell-programmed death. Cell apoptosis is how
cellular removal occurs and is advantagous to the life cycle of an organism. Perhaps the
most well known signal transduction cascade is the programmed cell death pathway of
apoptosis. Two classes of components govern cellualar apoptosis activity, the sensors
and the effectors. The sensors monitor the extracellular and intracellular envionment,
processing whether the conditions are abnormal and thus initiating the signal for
apoptosis. These lookout mechanisms are cell surface integrins whose signals
converge on the mitochondria. Here the bcl-2 family of proteins, whose members
include anti-apoptotic and pro-apoptotic constituents, supervise release of of cytochrome
C and p53, potent catalysts of cell death. In fact the tumor suppressor protein p53 is
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described by some as a „master watchman‟ implying its role in maintaining stability by
preventing genome mutation (30). The most common technique employed by a majority
of cancer cells to oppose anti-apoptotic signals involves the p53 supressor gene.
Inactivation of the p53 gene is seen in over 50% of human cancers and impinges on the
signal transductions of apoptosis (31). A great deal more about the characterization of
the bcl-2 family and the overexpression of the bcl-2 protein in ovarian carcinogenesis will
be discussed in Chapter 2 .4.

2.2.6 Limitless Replicative Potential
The previous three attained capabilites of cancer cells: GS independence,
insensitivity to anti-growth signaling, and opposition of apoptosis leads to the dire ability
of the disease to replicate without restrictions. All mamallian organisms possess an
intrinsic, autonomous cellular-program which restricts multiplication after a finite number
of replications. Therefore for clones of cancer cells to inflict a life-threatening tumor, not
only do they need to develop insensitivity towards anti-growth/pro-apoptotic signals but
they must also possess the capability to override inherent encoding of the target cell
(23). Once cells have progressed through their finite number of proliferation, they cease
propagating: a term called senescence. Rarely, a variant (1 in ~107 cells) mutant
emerges that has limitless replicative potential. Unfortunately, tumor cells grown in
culture possess immortality that is imperative for malignant cancerous states.
Telomeres, the ends of chromosomes which consist of several thousand short repeat
units of RNA, are progressively shortened after each proliferation. Eventually, the
telomeres are so short that they cannot protect the valuable chromosomal DNA, leading
to the ceasing of replication and further cell-maturation. 85-90% of cancer cells
upregulate expression of the telomerase enzyme, while others employ a technique
called alternative lengthening of telomeres (ALT), which preserves telomerase-activity
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through chromosomal information exchanges. By either upregulation of telomeric
enzymes or ALT numerous tumor cells achieve infinite replicative ability (32, 33).

2.2.7 Cancer Biomarkers: Pathway Modifications
The six hallmarks explored explicate specific techniques employed by the
progression of cancers and the affected cellular mechanisms. Since genetic and
molecular changes are the incipient events in development of cancer, the abundance or
lack of signal proteins, GF, specific DNA sequences, integrins, cadherins, cytokines or
any cellular indicator whose amplification or depletion indicates the carcinogenic
progression can be considered a cancer biomarker.

EARLY DETECTION

Figure 2.3 Biomarkers Indicate Onset of Disease. (11)

This research is predicated upon the cellular marker (bcl-2 protein) used by
ovarian cancer to avoid apoptosis. Biomarkers should be easy to detect, measurable
across populations and should provide evidence of early stage development of high-risk
individuals as seen in figure 2.3 above. Quantifying specific signaling manipulations that
tumor cells are responsible for (such as the silencing of pRb function in insensitivity
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towards GS and upregulating VEGF and FGF1 in chronic angiogenesis), is a first step in
elucidating biomarkers for early cancer detection. Hence, a variety of distinctive
biomarkers can indicate particular cancerous characteristics discussed above,
depending on the location of the tumor and defense mechanism manifested at the site.
That being said, the complexities of carcinogenesis and the multitudes of defensive
signal transductions occuring, often obscure the breakthrough.
The quantification of Dr. Patricia Kruk and her colleague‟s findings on the ability
of ovarian cancer to avoid apoptosis by manipulation of the bcl-2 protein has provided
the impetus to undertake this research and complete this master‟s thesis in hopes of
application towards an ovarian cancer recognition device in the near future.

2.3

Proteomics for Biomarker Discovery

The Human Genome Project was an international scientific research endeavor
aimed at identifying and mapping the approximately 20,000–25,000 genes of the human
genome from both a physical and functional standpoint (34). A working draft of the
genome was announced in 2000 and was completed in 2003, however the work on
interpretation of genomic data is still in its nascent stages. Knowledge of the human
genome provides new avenues for advancements in medicine and biotechnology. Many
budding molecular diagnostic companies such as Myriad Genetics and Cepheid have
developed easy ways to administer genetic tests that can show predisposition to a
variety of illnesses, including breast cancer, cystic fibrosis, sexually-transmitted diseases
and many others. Perhaps the greatest asset of the Human Genome Project is the
potential to ascertain the etiologies of cancer and other deadly diseases (35).
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As the genome is the complete set of genes in an organism, the proteome is the
entire set of proteins expressed by a genome, cell, tissue or organism. Simply put, it is
the set of expressed proteins in a given type of cells or an organism at a given time
under particular conditions. The word "proteome" is a blend of "protein" and "genome",
and was coined by Marc Wilkins in 1994 while working on the concept as a PhD student
(34). Whereas an organism‟s genome is unchanging, the entire set of proteins
expressed would vary from cell to cell and would be contingent upon the stimuli provided
by the micro-environment. The proteome is greatly larger than the genome because
there are more proteins than genes and consists of the entire complement of proteins
including the modifications made to a particular set of proteins (phosphorylation,
methylation, etc.) produced by an organism. The proteome reveals the intrinsic „genetic
code‟ of the cell as well as the influence of its micro-environment providing valuable
cellular signaling information. Since deeper understanding of the disease processes at
the level of molecular biology may determine new therapeutic procedures, proteomics
allows for the recognition of distinct biological changes caused by pathogens. These
changes include altered expression, protein modification, specific activity, inappropriate
localization, cell morphology: which can all contribute to damaged cellular function.
Fundamentally, proteomics is the systematic study of the correlation of gene activity and
protein expression in a cell at defined time (36). Since the proteome and gene
expression analysis methods are quantitative, new systematic approaches to
characterize protein functions in terms of the interaction within the cell, can lead to
discovery of early modifications of proteins (biomarkers) therefore detecting early
progression of diseases and potentially disease etiology.
Proteomics dates back to the late 1970s when researchers started to build
databases of proteins using the technique of two-dimensional gel electrophoresis (2DE)
(37). This resulted in general protein cataloging which resulted in the development of
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the first database of expressed proteins. Although the gels could be run reproducibly and
consistently, determining the identity of the proteins was problematic because of a lack
of sensitive and rapid analytical methods for protein characterization (such the
automated sequencer for DNA analysis that we possess today). In the 1990s, biological
mass spectrometry (MS) emerged as a powerful analytical method that removed most of
the limitations restricting extensive protein analysis. This progress, coupled with the
availability of the entire human coding sequence in public databases (via polymerase
chain reaction) marks the beginning of a new era in cancer biomarker exposition (38).
Today, the term proteomics covers much of the functional analysis of genomic effects or
„functional genomics‟, involving holistic proteome categorization and identification, as
well as specific protein-protein interaction analysis. Figure 2.4 provides a comprehensive
synopsis on the various techniques for proteome investigation done today. The four
major areas for proteomic research into the analysis of gene function and protein
expression and regulation are:

1) Molecular Anatomy: Analysis of protein composition of infectious cells and tissues.
2) Molecular Pathology: Analysis of disease‟s protein expression and modification.
3) Molecular Pharmacology: Effects of drugs on protein expression and modification
4) Molecular Physiology: Change in protein expression in response to the
environment.
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Figure 2.4 Defining Proteomics. (36)
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As mentioned in chapter 1.3, genetic and molecular changes are the incipient
events in development of cancer: The abundance or lack of signal proteins, growth
factors, specific DNA sequences, integrins, cadherins, cytokines or any cellular indicator
whose amplification or depletion indicates the disease progression can be considered a
biomarker (10). Proteomic techniques are the most useful approach to biomarker
discovery. Proteomics can be divided into two categories, described by their medium of
data evaluation: qualitative and quantitave. A review of selected techniques commonly
employed by researchers looking to investigate proteomics can be found in appendix A.

2.3.1 Challenges in Biomarker Validation
Many challenges still plague both proteomics and biomarker validation, namely
concomitant evaluation of oncogene pathogenesis via proteomics, tissue microarrays
and body fluid markers. Another major issue that arises is reproducible sensitivity and
specificity of biomarker levels in cancerous solutions. Currently, the major challenge is
analytical variability which creates a problem in identifying diagnostic patterns specific to
cancer states from the huge dynamic range of biomarker concentration and biological
inconsistencies among patient samples. For example, variation in sample collection,
handling, storage and profiling techniques may bias the protein profile obtained from a
given sample. It is progressively becoming more recognized that repetitive proteomic
assays should be applied in the clinical setting to increase reproducibility and validation
of cancer biomarkers. Presently effectively integrating proteomic, genomic and metabolic
data and their functional consequences in clinical results, will be of major interest.
Development of multivariate strategies for concurrent testing platforms is a potential step
towards validating carcinogenic biomarkers (39).
Before initiation of clinical testing it should be fully recognized that the specific
biomarker is truly in the pathway of the particular carcinogenesis and not simply the
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result of an adaptive response. Given the complexities of cancer progression, a
multitude of biomarkers spanning a variety or signal transduction networks should be
examined for more accurate cellular evaluation. Since a major concern for screening is
the eradication of false-positives, a wide variety of facets must display high specificity
including similarities between gender and races. Briefly, for a biomarker to be value
towards public health worldwide, the assay should be compliant to novel highthoroughput formats with minimal „false-positive‟ misclassifications.

2.4

The Role of the Bcl-2 Family in Tumorigenesis
Bcl-2 or B-cell lymphoma 2 is a protein which is named for being the second

member of a range of proteins initially described with chromosomal alterations in
follicular lymphoma patients (cancer of the immune system). It was first connected to
tumorogenesis in 1988 by the team of Cory and Adams, as they noticed chromosomal
translocations, or rearrangements, between positions 14 and 18 resulting in
overexpression of the anti-apoptotic bcl-2 gene ultimately contributing to follicular
lymphoma. This first introduced the thought that carcinogenic behavior can overexpress the bcl-2 protein to impair apoptosis (30). Over the years, Cory and Adams
have been pioneers in the study of the bcl-2 family and their role in apoptosis as well as
cancer progression. Because of their findings, the link between tumorogenesis and
apoptotic-regulation proteins was forever established. As a result, the prevalent
misnomer that proliferation and cell-death were under similar genetic control pathways
was eradicated and it was discerned that disturbances in both were likely to contribute to
neoplasia; signifying a major paradigm shift in the way cancer was subsequently
researched in a clinical setting (40).

28

Apoptosis, the most common form of programmed cell-death, is crucial for
formation of the embryo, maintenance of tissue, cellular homeostasis, terminating
immune responses, restricting the spread of infections and many other upkeep
responsibilities (cellular autophagocytosis, anoikis and necrosis are other examples of
programmed cell-death types). There are major signal transduction pathways, known as
„death circuits‟ that lead to programmed cell death (40). The apoptotic „death circuit‟ is
predicated on the recruitment of various caspases or cyteine-aspartic proteases, which
are enzymes that degrade polypeptides. To date, 12 caspases have been identified and
can be categorized into initiator or executioner caspases, indicating their contribution
towards programmed cell death. As cells perform apoptosis various caspases are
cooperatively responsible for: irregular bulging of the plasma membrane (blubbing),
nuclear fragmentation, chromatin condensation and internucleosomal DNA cleavaging
and finally removal from the cell through vesicle. The elucidation of the „death circuits‟
pathways over the past two decades has raised the possibility of developing therapies
that aim at ensuring the inclusion of pro-apoptotic proteins that cancers aim to exclude
(30,41).

2.4.1 Bcl-2-Like Proteins: Systematic Control over Apoptosis
Bcl-2-like proteins consists of fully homologous and BH3-only proteins that are
the central reason for activation (pro-apoptotic) and inactivation (anti-apoptotic) of an
inner mitochondrial permeability transition pore. Activation of this pore induces
biochemical stimulus to initiate caspase activity. Therefore, the specific bcl-2 protein is
not a strict cell-death regulator, rather it is a range of interactions between a proapoptotic and anti-apoptotic constituents of the “bcl-2 family” that govern the cell‟s fate
(figure 2.5). There are 25 genes that display one or more of the four structural domains
of homology, entitled the bcl-2 homology (BH1, BH2, BH3, BH4). All anti-apoptotic
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proteins contain the BH1 and BH2 domains, and a select few contain an additional BH4
domain. The extent of knowledge about the functional responsibilities of the BH1, BH2

Figure 2.5 Bcl-2 Family Structure. (30)
a) Pro cell-death constituents b) Anti cell-death constituents
and BH4 domains are very limited, however there is a great deal known about the BH3
domain. Sole possession of this domain (BH3-only proteins) indicates pro-apoptotic
behavior. These members bind to specific pro-apoptotic proteins of bcl-2 family which
leads to their killing in continuation of the anti-cell death defense mechanism component
of innate immunity (42, 43). The BH3 domain is also present in some anti-apoptotic
proteins as well. It has become increasingly evident that since its‟ initial inception every
cell requires protection by at least one of the bcl-2 homologues. It is no surprise
therefore, that abundance of the wide range of bcl-2 homologues indicates tissue
homeostasis in organisms. Prominent apoptotic contributors or bcl-2-like proteins are
introduced below.


The fully homologous constituents consist of five anti-apoptotic proteins, (Figure
2.5a): Bcl-2: B-cell lymphoma, Bcl-xL (BCL2L1): B-cell lymphoma-extra large,
Bcl-w (BCL2L2): Bcl-2-like protein 2, MCL1 (BCL2L3): Myeloid cell leukemia
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sequence 1, A1 (BCL2A1): Bcl2-related protein A1 and two pro-apoptotic
proteins: BAK (BCL2L7): Bcl-2 homologous antagonist/killer, BAX (BCL2L4): Bcl2-associated X protein (30,41,43).


Eight known BH3-only proteins induce pro-apoptotic signals, (Figure 2.5b): BIM
(BCL2L11): Bcl-2-like protein 11, BAD (BCL2L8): Bcl-2-associated death
promoter, NOXA (PMAIP1): PMA-induced protein 1, PUMA (BBC3): Bcl-2binding component 3, HRK (BID3): BH3-interacting domain-containing protein 3,
BIK: Bcl-2-interacting killer and BMF: Bcl-2-modifying factor (30, 41).
Although knowledge is limited regarding the functions of the fully homologous

members, it is known that bcl-2 is required for survival of mature T and B lymphocytes.
As a matter of fact, bcl-2 is linked to many tumor types overexpression is often
connected to poor survival (30, 44). Similarly, Bcl-xL is essential for regulating platelet
survival, thus deficiency of the protein might be expected to cause thrombocytopenia or
the lack of platelets in blood cells. Both bcl-2 and Bcl-xL bind to the BH3 domains of the
tumor-suppressor beclin 1 (BECN1) which has shown to inhibit autophagy, thus
indicating the bcl-2 families contributions to programmed cell death extend further than
apoptosis. MCL-1 is required for the survival of hematopoietic stem cells and BCL-w is
vital for the appropriate development of sperm cells. A1 acts as an apoptosis retardant
for blood cells.
To initiate cell death in a healthy cell, BAK or BAX must be relieved of its
suppression by the relevant pro-survival proteins. BAK is widely expressed in the
mitochondria while quiescent BAX is located in the cytosol and is recruited to the
mitochondria once cell apoptosis is commenced. For BAX mediated cell death, binding
to bcl-2 is essential whereas MCL1 and Bcl-xL are vital in BAK mediated cell death.
BAX and BAK oligomers are credited to provoke the permeabilization of the outer
mitochondrial membrane which engenders signaling which is conducive for the initiation
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of caspase-mediated cell death. Cytochrome c, an intermediate mechanism in
apoptosis, is a large transmembrane protein that is released by the mitochondria in
response to pro-apoptotic stimuli and is preceded by elevation in calcium levels. The
release of cytochrome c, coupled with presence of apoptosis-activating factor 1 (Apaf1)
in turn binds and cleaves caspase 9, the initiator caspase causing mitochondrial death.
The apoptotic „death circuit‟ pathway is completed with activation of executioner
caspases 3 and 7 (51).
On the other hand, selective interactions of BH3-only proteins and their prosurvival family are well documented. Tissue homeostasis seems to be impinged by the
disruption of the balance between pro-survival and BH3-only proteins. The majority of
the BH3-only proteins act by binding to and neutralizing of their anti-apoptotic relatives,
(table 2.2). Perhaps, the small allosteric change generated in the pro-survival proteins by
binding with a BH3-only domain affects the association with other proteins in the antiapoptotic pathway. Thus the BH3-only proteins allow for a greater degree of control
over cell death. BID has a vital role in initiation of apoptosis, as it leads to the activation
of BAX and BAK and when both of these proteins are excessive, it rapidly (less than a
minute) triggers cytochrome c release (43,45).
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Table 2.2 Binding Affinities: Bcl-2 Family of Proteins.
Dissociation constants (nM) for interactions between pro-survival BCL-2 family proteins
(left column) and BH3-only proteins (top row) are shown. Standard deviations in
parentheses. Yellow blocks signify high-affinity binding; blue blocks signify no observed
binding. Activators in purple, sensitizers green. (30,41,43)

2.4.2 Validation of Bcl-2 as an Ovarian Cancer Biomarker
The uncovering of cell-death pathways over the past two decades has made it
possible to target apoptotic proteins to potentially develop therapeutics for cancer and
inflammatory disease, as well as diagnostic devices for recognition of tumorigenic
stages. While apoptosis is an essential biological process for the development and
upkeep of tissue homeostasis it is also centrally involved in a number of degenerative
diseases, immunological diseases and cancers (46). Since the bcl-2 family strictly
regulates apoptotic initiation and execution, both pro-apoptotic and anti-apoptotic can be
targeted for apoptotic-antagonists and biomarker discovery.
Validation of biomarkers is an elaborate process because of problems that arise
with the reproducible sensitivity/specificity of biomarker levels in samples and the
analytical variability connected with identifying diagnostic patterns specific to cancer
states. Variations in sample collection, handling, storage and profiling techniques may
bias the protein profile obtained from a given sample. According to the National Institute
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of Standards and Technology (NIST), as newly discovered biomarker assays progress
from a research setting to the clinical diagnostic laboratory, it should proceed through
defined stages of assay confirmation. The preliminary check for biomarker validation is
the evaluation of research assay technology, performance, and specifications (analytical
validation). Ultimately, the biomarker must detect early stage cancer in a clinical setting
(clinical validation). Upon analytical and clinical confirmation, assays are moved
systematically toward a standardized, reproducible, high-throughput format for clinical
diagnostic implementation (47).
Examination of the analytical validation of bcl-2 as a cancer biomarker began
with a pilot study done from Brazil in 2002. A research team evaluated the importance
of p53 and bcl-2 levels in epithelial ovarian cancer, (p53 is a tumor suppressor protein).
Tumor tissues from 90 patients were analyzed immunohistochemically for p53 and bcl-2
expression resulting in forty-two (47%) positive for p53 expression and 18 (20%) positive
for bcl-2 expression. Positive expression for p53 was less frequent in stage 1 patients
(22%) and no direct correlations could be demonstrated between p53 and bcl-2
expression and age or histologic grade. Thus, p53 and bcl-2 expression were not
significantly correlated with overall survival, disease-free survival, or progression time
(46). By 2004, clinical papers had been accepted for correlation of bcl-2 levels in a
variety of mature peripheral B-cell tumors: B-cell chronic lymphocytic leukemia (B-CLL),
diffuse large B-cell lymphoma (DLCL), multiple myeloma (MM) and B-cell precursor
acute lymphoblastic leukemia (BCP-ALL) (14). The work on elevated bcl-2 levels found
in the urine of ovarian cancer patients at the University of South Florida provided the
proper clinical validation providing essential impetus for the research in this thesis. In
the study two cohorts provided blood and urine samples from women, the first consisting
of 92: 19 healthy controls, 38 assorted benign gynecological disorders, 4 with early
stage (EOC) and 31 with late stage ovarian cancer (LOC). The second consisted of
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296: 58 healthy controls, 123 assorted benign gynecological disorders, 9 with EOC and
106 with LOC. Though it was not seen in the serum, perhaps due to the presence of
confounding proteins, the elevated urinary Bcl-2 levels showed a direct correlation with
presence of ovarian cancer (6). The average urinary levels of the Bcl-2 : Healthy:0.59
ng

/ml Benign:1.12 ng/m EOC: 2.60 ng/ml and LOC: 3.58 ng/ml as seen in figure 2.6.

Figure 2.6 Urinary Bcl-2 Levels Elevated in Ovarian Cancer Patients. (6)
In addition, when compared to the CA125 levels which have been shown to be
elevated in ovarian cancer (along with benign gynecological disease and hepatic
disease), bcl-2 levels showed a favorable correlation. This not only provided further
corroboration for Bcl-2 as a biomarker, but also allowed for dual proteomic screening for
flawless ovarian cancer diagnosis. It was noted that bcl-2 did not suffer from the falsepositives that plague CA125 screening and it was concluded that bcl-2 over-expression
in bodily fluids that could result in a novel biomarker for ovarian cancer (6). This is the
validation that we need to use the standard bcl-2 protein in this research as an analyte
on functionalized surfaces to potentially be implemented in a POC diagnostic.
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CHAPTER 3: REAGENTS USED TO FUNCTIONALIZE SURFACE
3.1

Bioconjugation
The technology of bioconjugation over the past decade, has influenced nearly

every research branch of the life sciences. Bioconjugation involves novel molecular
linking of two or more particles to construct a compound that has properties of its
individual constituents. Simply, bioconjugation allows the molecular self-assembly of
several reagents with varying properties for a desired purpose. Natural occurring
biological systems are often the inspiration that loosely provide „templates‟ for novel selfassembly. Biologically assembled compounds can be chemically amalgamated resulting
in unique structures with carefully engineered properties. Today, bioconjugation has
become a billion dollar industry spanning research in diagnostics, biomarkers and
biosensors to name a few (48).
Bioconjugation techniques can be applied to modify the native conformations and
overall functions of polysaccharides, nucleic acids, lipids, oligonucleotides, etc. By
distinctively conjugating molecules to interact with target analytes in solution,
bioconjugation has quickly become a staple of all biological assays in a clinical setting.
As a matter of fact, anything that can be chemically derivatized, or isolated, can be
conjugated onto inorganic silica or metallic substrates. Proteomic molecules are
generally the most common targets for conjugation methods. Through deliberate
modifications which allow for specific proteomic binding to a particular target molecule,
structure and function of proteins can be elucidated. In this way, without the
development of conjugated, labeled and modified molecules the majority of life science
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research done today in a laboratorial setting would be impossible to achieve. Thus,
molecular self-assembly provides this research with methods to isolate the bcl-2 protein
in solution via specific binding to a polyclonal capture antibody which is immobilized due
to linkaging of various reagents on glass cover slips.
The methods of molecular self-assembly employed in this research deals with
supramolecular chemistry. The forces that directly order of the spatial organization of
the self-assembly, are varied from weaker intermolecular (hydrogen bonds or van der
Waals forces) to stronger covalent linkages. The study of non-covalent interactions is
crucial to understanding many biological processes from cell structure to protein
conformation that rely on these forces for organization and function (48).
A self-assembled monolayer (SAM) is the organization of head groups on an
inorganic substrate by chemisorption, followed by dense organization of the tail or
reactive groups (as seen in figure 3.1). The ability to customize both head and tail

Figure 3.1 Self-Assembled Monolayer.
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groups of the constituent molecules makes SAMs excellent systems for a more
fundamental understanding of a wide variety of biological phenomena including disease
etiology and pathology. SAMs are the precursor to a great deal of bioconjugation
techniques as it allows the functional groups to be „built upon‟ once the head groups are
conjugated on the substrate. In 1946, Zisman published the preparation of a single
monolayer layer of a surfactant by adsorption onto a clean metal surface (49). Though
at the time the relevance of the research was not fully comprehended, this was the first
formation of a monolayer by self-assembly and thereby laid the foundation for the fields
of bioconjugation and supramolecular chemistry. Just as research in bioconjugation has
made great strides as of late, the field of SAMs has witnessed tremendous growth in
synthetic sophistication and quality of characterization. SAMs offer inimitable
opportunities to expand fundamental understanding of self-organization, interfacial
phenomena and receptor-ligand interactions. Independent control of surface structure
and the respective chemical properties are not only scientifically stimulating, but
technologically applicable. Since functionalization can occur on many different materials
with a large number of molecular structures, the flexibility that SAMs allow for them to be
a vehicle for investigation of specific interactions at potentially every biological-interface
imaginable (50).

3.1.1 Molecular Self-Assembly Reagents Used
The novelty of this research lies in the fact that it is the first of its kind to attempt
to isolate the bcl-2 protein using novel functionalized surface assemblies. Through
manipulation of derivatized reagents to target the functional bcl-2 protein, we can
compare the overall capture from the bioconjugated substrates with known urinary levels
in ovarian cancer patients (6). In this chapter, the various bioconjugation reagents that
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are used are introduced and their functional properties and desired functions are
elucidated. Briefly, the process of oxygen plasma cleaning results in the dispersion of
hydroxyl groups onto the surface, which serves as the proper initiation technique to
attach a monolayer of an organofunctional silane on the substrate. This silanization
process creates SAMs on the substrate and acts as a link to connect an otherwise
inorganic surface with organic molecules, allowing for subsequent molecular assembly
on the functional tail group. By linking the silane and a known immobilizer of antibodies,
protein A/G, correct orientation of the bcl-2 antibody can potentially be achieved. Two
methods are used for protein A/G recruitment: mimicking of hydrophobic in vivo binding
sites of proteomic targets in our bodies by directly adsorb on the ODMS and secondly,
use of amine-reactive homobifunctional reagents to crosslink onto the 3-APTMS (51).
Lastly, a non-fouling surface must be maintained by introducing chains of (poly)ethylene
glycol (PEG) and if adsorbed extensively, will allow the substrate to be resistant to nonspecific binding. Through extensive research into assembly techniques using various
reagents, five target surfaces are functionalized and subjected to novel ELISA assay
quantification. All of these bioconjugations reagents will be explored in this chapter.
For the research to be diagnostically applicable, certain factors reveal
themselves as more important than others. First of all the substrate must display highly
specific capture of the bcl-2 analyte, via high affinity of a bcl-2 recognizing capture
antibody. Secondly, since a diagnostic device can be rendered inaccurate if it provides
false-positive results, the quantification of only bcl-2 must be achieved. By successfully
introducing PEG layers onto the surface, background has been shown to be eliminated
and a non-fouling surface, void of any non-specific binding, can be upheld (52). Three
different PEGylation reagents are experimentally varied, to assess the efficacy of
attachment on the surface. Moreover, the substrate with the highest capture of bcl-2
with the lowest background non-specific binding serves as the ideal bioconjugated
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platform. Other relevant factors which potentially can affect the assembly, such as
surface energy and wettability parameters are also varied in the experimental setup as
an amine reactive hydrophilic silane (3-APTMS) is tested against a hydrophobic silane
(ODMS). Once the head groups of each silane could be covalently linked, the functional
tail allowed for bioconjugation on the substrate to orient the antibody (anti-bcl2) needed
to target the analyte bcl-2 protein. To arrive at the most effective assembly method, a
rigorous literature review revealed target reagents.
Antibodies are expressed as IgA, IgD, IgE, IgG and IgM and they each
correspond to different sequence homologies and therefore different ligand binding
which results in initiations of a multitude of signal transductions. In its four forms, IgG,
provides the majority of antibody-based immunity against invading pathogens. It is well
established that the “Y” shape of IgG has Fab (antigen binding) and Fc (constant) regions,
as seen in figure 3.2. Upright orientation ensures that maximum binding can occur with
the desired analyte and confirms that the Fab receptors are sterically unrestricted,
increasing the desired proteomic binding. There are a number of immunoglobulin
binding proteins which are used in biological research to purify, immobilize or detect
immunoglobulins by binding their Fc domains which include: Staphylococcal Protein A, G
and L (protein-A, protein-G and protein-L) (53, 54).

Fab

Fab

Fc
Figure 3.2 Antibody Structure.
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Protein-A/G is a recombinant protein that combines IgG binding domains of both
protein-A and protein-G ensuring maximum antibody recruitment. Protein-A/G contains
four Fc binding domains from Protein A and two from Protein G. The binding of proteinA/G is less limited than Protein A which is of the dependent upon pH and has the
additive properties of protein-A and protein-G. A great deal more about protein A/G is
mentioned in chapter 3.3.1.

3.1.2 Test Substrates Chosen
To ensure that the surfaces displaying the highest efficacy of capture were
arrived at, a variety of reagents were used (table 3.1). The commonly used amine
crosslinking technique was employed in substrates 1-3 to covalently link the protein-A/G
on the 3-APTMS SAM by targeting amine groups (51). Hence the proven aminecrosslinking method was experimentally tested against direct physical absorption of
protein-A/G on hydrophobic surfaces. Subsequently, all of the substrates received a
polyclonal anti-bcl2 IgG that would recruit the analyte protein. The final step in the
functionalization was to ensure widespread integration of PEG chains on to the surface
to maintain a non-fouling surface, thereby only allowing specific bcl-2 capture.

Table 3.1 Experimental Surfaces Chosen.
Substrate
#

1
2
3
4
5

Silane Used
3-APTMS

Orientation By
Gluteraldehyde
(GA)-A/G

3-APTMS
3-APTMS

Capture
Antibody

Surface Block

anti-bcl2

MS(PEG)4

BS(PEG)5-A/G

anti-bcl2

BS(PEG)5

BS(PEG)5-A/G

anti-bcl2

BS(PEG)5

ODMS

protein A/G

anti-bcl2

MS(PEG)4

ODMS

protein A/G

anti-bcl2

Pluronic
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MS(PEG)4

Three PEGylation reagents were tested, two being amine reactive BS(PEG)5 and
MS(PEG)4 and the third a triblock copolymer named Pluronic F127. Table 3.1 explores
the five functionalized surfaces whose silanes, crosslinkers and PEGylation reagents
displayed the most effective self-assembly. Commonalities between the surfaces
include initial plasma cleaning and introduction of hydroxyl followed by a silane
treatment, protein-A/G recruitment to orient the primary antibody and adsorption of a
surface block with PEG layers to ensure prevention of non-specific binding. All of these
reagents and their reactive chemistries will be discussed at greater lengths in later
sections of this chapter. A schematic displaying reagent assembly on the 3-APTMS
based glass substrates can be seen in figure 3.3 below.

Figure 3.3 Schematic of 3-APTMS Surface Functionalization.

Substrate 1, 2 and 3 all employ the amine-crosslinking chemistry seen above
with the blue arrows, with GA being used in substrate 1 and BS(PEG)5 in substrate 2
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and 3 to recruit protein A/G to orient the antibody. To avoid non-specific binding,
substrate 1 and 3 link MS(PEG)4 after the capture antibody and substrate 2 uses only
BS(PEG)5. The PEG chains can be seen with the red lines. Below, in figure 3.4, a
schematic displaying reagent assembly on the ODMS based substrate can be seen.

CH2 CH2

CH2 CH2 CH2

Figure 3.4 Schematic of ODMS Surface Functionalization.

Substrate 4 and 5 employ the direct physical adsorption of protein A/G (in orange) on the
hydrophobic silane to recruit the capture antibody. Substrate 4 adsorbs MS(PEG)4 on
the surface and substrate 5 uses Pluronic to maintain a non-fouling surface after the
antibody step (red chains).
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3.1.3 Validation of Substrate: Contact Angle Measurements
Selection of the test surfaces was not as linear as simply choosing the reagents
and randomizing the order for assembly on the substrate. Rather, once the most
suitable reagents were arrived upon, an analysis on the surface properties was
conducted through sessile contact angle measurements. This revealed the critical
surface tension and adhesion properties, which allowed for investigation into the extent
of effective binding occurring on the test surfaces. Gathering measurements at each
step of the bioconjugation process and determining surface contact angles between the
applicable silanes, homobifunctional crosslinkers and PEGylation reagents revealed if
proper reagent coverage was occurring on the substrate. Since each reagent is
expected to engender distinct fluctuations in the overall substrate surface energy,
statistically relevant variations in contact angle measurements can perhaps indicate
suitable reagent coverage. Thus, by identifying relevant changes in contact angle
measurements, the validation of the techniques to recruitment protein A/G and
PEGyation reagents on the 3-APTMS and ODMS substrates could be arrived at.
According to Gelest‟s handbook on hydrophobicity, hydrophilicity on silane
surface modification, any surface with less than 30o contact angle with water can be
considered hydrophilic and greater than 90o to be hydrophobic (51). This is will serve as
a good parameter to discuss the findings, as the contact angle measurements were
tested with deionized water (diH20). A KSV CAM 101 contact angle measurement device
was used to gather sessile contact angles of the glass substrates. Since the two major
factors that need to be addressed in this research are efficient tethering of antibodies via
protein A/G immobilization and elimination of non-specific binding via recruitment of
PEGylation reagents, these two issues will be addressed by both the contact angle
measurements as well as analysis of the chemistries of the various chemistries. Figure
3.5 display an analysis of the contact angles of an amine-crosslinker, GA, on both
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silanes. It should be noted that all data has been statistically verified with a significance
level (p-value) of 0.05 unless otherwise mentioned. Also, all of the contact angle
measurements found in this research can be found in appendix C.

120

Amine Crosslinking on Both Silanes

100

Contact Angle

80

Silane
GA
Protein A/G

60

40

20

0

3-APTMS

ODMS

Figure 3.5 Efficacy of Amine-Crosslinkers to Recruit Protein A/G.

Contact angles obtained from both organofunctional silanes were as expected
with the ODMS displaying hydrophobic properties and 3-APTMS being very close to
published results (51). When adsorbing protein A/G on both silanes with the prior
adsorbtion of GA: we see a statistically significant increase in hydrophilic behavior
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(45.9 o vs. 36.3o) for the 3-APTMS and statistically insignificant increase in hydrophilic
behavior for the ODMS (84.525o vs. 81.044o). It can therefore be established that
ODMS is an inefficient silane to adsorb an amine-crosslinkers to immobilize protein A/G
upon. This conjecture is achievable because of the published research into GA being
able to covalently link with amine groups (48, 53), present on protein A/G and 3-APTMS.
As a result, the biological evidence of proteomic binding in hydrophobic settings was
mimicked in the research to physically adsorbing the protein A/G on the ODMS (51).
Consequently, direct physical adsorption of protein A/G on the hydrophobic ODMS will
be tested against the introduction of amine-reactive homobifunctional crosslinkers, GA
and BS(PEG)5, on the 3-APTMS test assemblies to crosslink protein A/G. Following
protein A/G all test substrates will be introduced to the polyclonal capture antibody.
The resilient linkaging of PEG layers onto the test substrates was also tested
with the sessile drop technique. Consequently, the 3-APTMS with GA and A/G and the
ODMS with A/G had all three non-fouling surfactants adsorbed and were examined for
contact angle measurements. Since the PEGylation reagents increase surface
wettability, (because of PEG repeat „mers‟), we can gauge the effective adsorption or
covalent linkaging of the PEG chains on the surface by observing the smallest contact
angle found on each substrate (55). Since an increase in surface wettability represents
an increase in hydrophilic behavior, the reagent that can decrease the samples contact
angle are of interest, especially for the ODMS because of its‟ innate hydrophobic
properties. Figure 3.6 illustrates the effective recruitment of the three PEGylation
reagents onto the 3-APTMS and the ODMS substrates.
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PEGylation Reagents on Both Silanes
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Contact Angle
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MS(PEG)
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3-APTMS, GA-A/G

ODMS & A/G

Figure 3.6 Efficacy of PEGylation Coverage on Both Silanes.

Covalent linking of the BS(PEG)5 was efficiently done on 3-APTMS, which can
be seen by the extremely hydrophilic behavior. This results were expected and this
demonstrated that the BS(PEG)5 is a versatile complex for amine-crosslinking as well as
PEGylation on the silane. For this reason, it is used in two of the 3-APTMS assemblies,
substrates 2 and 3. However, it did not increase the hydrophilicity of the ODMS to the
extent that might be expected. Since ODMS does not introduce amine groups on the
surface, the amine reactive N-Hydroxysuccinimide (NHS) ends of BS(PEG)5 were
perhaps not be linked to the surface. Furthermore, due to its short length and
hydrophilic nature, it is unlikely to adsorb this reagent to the hydrophobic ODMS.
47

The MS(PEG)4 has four repeat PEG „mers‟ with an amine reactive NHS ester on
one end and an unreactive hydrophobic methyl group on the other. When attached to
the surface a „brush‟ of PEG chain is formed. For the 3-APTMS, the hydrophobic methyl
group present at the free end of MS(PEG)4 influenced the contact angle and may be the
reason for the increase in hydrophobicity compared to the BS(PEG)5 (57.7o vs. 25.4 o).
There is also a statistically relevant difference in contact angle for the ODMS substrates
with MS(PEG)4 compared with BS(PEG)5 representing enhanced coverage perhaps
because of inherent affinity of the silane to the methyl-terminated tail of the MS(PEG)4.
For this reason it is employed in substrate 4 to test the value of the PEGylation reagent.
Finally contact angle measurments were taken for the Pluronic F127, which is a
tri-block copolymer composed of a central hydrophobic chain of poly-propylene oxide
(PPO) enclosed by two hydrophilic PEG chains. Pluronic resulted in the highest surface
energy for the ODMS representing the reagent‟s worth for PEGylation coverage on
hydrophobic substrates (55). Conversely, for 3-APTMS we see an increase in
hydrophobic behavior with adsorption on the surface or a decrease in surface energy.
Interestingly, there is not a statistical difference between the measurements found from
the 3-APTMS assembly with Pluronic and MS(PEG)4 (56.0o vs. 57.7o). A potential
explanation for this is that the PEG chains are highly attracted to the hydrophilic 3APTMS surfaces, causing inverse binding of the Pluronic with the hydrophobic PPO
section to be oppositely oriented. Further insight into this as well as a figure of Pluronic
is found in section 3.4. The variability of the validated reagents‟ bioconjugation upon the
two distinct organofunctional silanes can be seen on the next page in figure 3.7
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Figure 3.7 Variability of Reagents on the Test Substrates.

3.2

Organofunctional Silanes
The linking between inorganic substrates and organic building blocks for

bioconjugation is a key aspect of surface functionalization. It has been shown over the
years that organosilanes are the most effective at creating widespread, tough covalent
linkages or SAMs on a variety of metallic and silica surfaces. Organosilanes contain at
least one silicon-carbon bond. The carbon-silicon bond is very stable and possesses a
unique tendency in nature to form four covalent linkaging, thus being ideal for molecular
self-assembly techniques. Organofunctional silanes are molecules carrying two different
reactive groups on their silicon atom so that they can react and couple with inorganic
surfaces (56). The value of organofunctional silanes as coupling agents was discovered
in the 1940s, during the development of fiberglass-reinforced composite beams (50).
Some common applications for silanes today are the windshield coatings by creation of

49

strong hydrophobic layer, as additives in inks, coatings and sealants to improve
adhesion and in plastics/rubbers to allow for cross-linking. Many combinations are
possible between the molecular constituents of silanes, however the only prerequisites is
that the head group is hydrolyzable (such as alkoxy or chlorine), so it can build strong,
tight bonds with solids. The large number of possibilities of hydrolyzable head groups
(1-3) and organofunctional ends make silanes extremely adaptable to many applications
in life science as well as nanotechnological research (57).

Figure 3.8 Chemistry of Organofunctional Silanes.

3.2.1 Chemistry of Silanization
Today, silanization is a commonly practice which uses biochemistry properties in
novel methods for a wide variety of applications. Because of this, silanization is
employed in a range of engineering fields for microfabrication, crosslinking and selfassembly. Most of the widely used organosilanes possess an organic substituent (tail
groups) and one to three hydrolyzable substituents (head group) (56). This can be seen
in figure 3.8, where the X‟s are the hydrolyzable groups and R is the organofunctional
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group. It should be noted that silicon reacted with three alkyl groups are usually referred
to as a silyl group. These hydrolyzable groups merge the linkage with the inorganic
substrate in well-documented steps. The first step is the physical adsorbtion of the
silane onto the silica substrate, where hydrolysis occurs of the hydrolyzable head
groups. The majority of silanes have linking groups containing a silane binded to three
actively saturated hydrogen-carbon molecules (trialkoxyl-silane). Formation of silanol
(Si-OH) groups from the initial silyl groups occurs through hydrogen bonding. These
silanol groups can then condense with each other to form the final monolayers with
covalent siloxane bonds (Si-O-Si). The self-organization that ensues is driven by the
van der Waals interactions amongst adjacent alkyl chains (51, 56).
The formation of covalent bonds to the surface ensures a certain amount of
reversibility. Because of this silanes with three alkoxyl groups are widely used to
crosslink inorganic substrates. Levels of hydroxylation on the substrate are also a factor
when attempting to silanize. An important issue in controlling the effectiveness and
overall surface properties is the linker length (CH2)n. Typical linker length is three carbon
atoms which is suitable for inorganic-based molecular self-assembly (56). Because of
the steric constraints imposed by inorganic surfaces, the linker length allows greater
mobility of the organofunctional groups. Simply, longer linker lengths have shown to
create dense SAMs which correspond to a larger surface area for bioconjugation.
However, it has been found that excess in linker length (greater than 18 carbon atoms)
in silanized SAMs causes mingling of chains and thus a high level of disorder (57).
Depending on the application of the silane, a monolayer or multilayer adsorption may be
desired. The thickness of a polysiloxane layer is regulated by the concentration of the
siloxane solution and is also a factor which governs surface properties. It has been
calculated that deposition from a 0.25% silane solution onto glass could result in three to
eight molecular layers, which is suitable for creating a platform for bioconjugation (51).
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3.2.2 3-Aminopropyltrimethoxysilane
3-APTMS is a common organosilane used with a wide variety for crosslinking
molecular reagents especially in proteomic analysis because of the presence of the
amine group in its functional tail (57). A figure of 3-APTMS (figure 3.9) shows that it has
a molecular formula of H2N(CH2)3Si(OCH3)3, density of 1.027 g/ml and a molecular weight
of 179.29 g/mol (58). A schematic of 3-APTMS was retrieved from the Sigma-Alrich
website. It can be seen that the hydrolyzable head consists of three methoxy groups,
which create a highly polymerized SAMs on the substrate. 3-APTMS has a short
organic 3-Amino(Propyl) group which terminates in a primary amine. This allows 3APTMS to be react with GA-mediated linkaging, or other amine-related tethering.
Essentially, any crosslinking reagent containing an amine reactive group can be used to
modify the hydrophilic silane surface. The silane can be diluted in any anhydrous
solvent such as toluene, in preparation to be covalently linked to inorganic substrates.
3-APTMS will be linked to amine-reactive homobifunctional crosslinkers (chapter 3.3), in
hopes of efficiently tethering of protein A/G. It should be noted that the 3-APTMS
surface may contain some thick hydrophobic patches due to the random polymerization
and may contain unreacted methoxy groups, which can lead to increased background
via nonspecific interactions with untargeted protein molecules (59).

Figure 3.9 3-APTMS Structure. (58)
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3.2.3 Chlorodimethyloctylsilane
ODMS has a molecular formula of CH3(CH2)7Si(CH3)2Cl, density of 0.836 g/ml and
a molecular weight of 179.29 g/mol (60). A schematic of ODMS was retrieved from the
Sigma-Alrich website (figure 3.10). It can be seen that the ODMS methyl groups (CH3),
both to crosslink to the substrate and as organofunctional tail to allow for molecular selfassembly to occur. However ODMS only has one hydrolyzable groups, two less than
the highly reactive 3-APTMS. Intuitively, this may seem to be detrimental to the
successful functionalization on the inorganic surface. However, it was noted that the
lack of hydrolyzable groups may have favorable effects on the SAM organization. This
was determined by the overall hydrophobic characteristics of the substrate (roughly
101o) as well as clear uniform deposition on the surface, because of the presence of a
single hydrolyzable Si-Cl bond. Whereas the 3-APTMS substrates appeared semitransparent, due to unregulated silanol formation, ODMS substrates remained clear
indicating well-defined, tight monolayer dispersion. Thus, the sole hydrolysable group
on the ODMS provided a consistent, homogenous base for subsequent bioconjugation
to occur. Because of this the ODMS could be concluded as the more reproducible
silane of the two.

Figure 3.10 ODMS Structure. (60)
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3.2.4 Methods and Materials for Plasma Cleaning and Silanization
Deposition of silanes from aqueous alcohol based solutions is the most facile
method for preparing silylated surfaces on inorganic substrates and this method will be
employed in this research. Before silanization and bioconjugation on the square glass
slips, they must be thoroughly cleaned and have hydroxyl dispersion on the surfaces. To
accomplish this they were subjected to five minutes of plasma treatment in the PE-50
benchtop plasma cleaner,. The square glass substrates were purchased from Bellco
(catalog number 463109, model number 1916-09009) and had a side length of 9 mm.
Before entering the oxygen plasma cleaner, the glass cover slips were also thoroughly
cleaned with nitrogen (N2). The silanes were diluted in anhydrous toluene, which was
purchased from Sigma Aldrich (product number 244511). The plasma cleaner
successfully removes any organic materials and oxidizes the surface, providing high
density of hydroxyl (-OH) groups for silane reactions to occur.
3-APTMS was purchased from Sigma Aldrich (product number 281778).
Anhydrous liquid phase deposition was done by dissolving the silane in toluene.
Toluene was purchased from Fisher Scientific (product number T324). A working molar
concentration of 0.1 Moles/Liter is desired in toluene, to covalently link the silane to the
inorganic substrate. Since the molecular weight for 3 -APTMS is 179.29 grams/mole and the
density is 1.027 grams/mole; the volume of silane needed can be calculated. Sample
calculation can be seen below for diluting a total of 20mL of 3-APTMS to 0.1M.
(

)(

)(

)

(.02L) (0.1 M/L) (179.29 grams/M)
.3586 grams
3-APTMS needed = (

)⁄ (

3-APTMS needed = (0.3586 grams)/ (1.027 grams/ml)
3-APTMS needed = 0.349 mL

349 µL
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)

After the samples have been oxygen plasma cleaned, they were careful deposited in the
solution for a fixed duration of 1 hr at room temperature. After the hour, the samples
were thoroughly rinsed with generous amounts of toluene then ethanol and
subsequently blow-dried with N2.
ODMS was purchased from Sigma Aldrich (product number 246859). Anhydrous
liquid phase deposition was done by dissolving the silane in toluene. A working molar
concentration of 0.1

Moles

/Liter is desired in toluene to covalently link the silane to the

inorganic substrate. Since the molecular weight of the ODMS is 206.83 grams/Mole and the
density is 0.836 grams/Mole; the volume of silane can be calculated. Sample calculation can
be seen below for diluting a total of 20mL of ODMS to 0.1M.
(

)(

)(

)

(.02L) (0.1 M/L) (206.83 grams/M)
.41366 grams
needed = (
needed = 0.474 mL

)⁄ (

)

474 µL

Post oxygen plasma cleaning, the samples must be carefully deposited in the solution
for a fixed duration of 1 hour at room temperature. After the hour, the samples were
thoroughly rinsed with toluene and ethanol and subsequently blow-dried with N2.
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3.3

Immobilization of Antibodies
Antibodies are an ideal tool that are used in variety of diagnostics, enzyme-linked

immunosorbent assays (ELISA) and biosensors (59). The high specificity that
antibodies display towards discrete proteomic targets essentially guarantees recruitment
of target proteins, allowing for novel assays and protocols to be established in a variety
of engineering, chemistry and biological fields. The term antibody and immunoglobulin
are often interchangeably used as antibodies are glyco-proteins that belong to the
immunoglobulin family. Of them, IgG is the most prevalent type of surface
immunoglobulins. IgGs are thus the basis of affinity techniques to biologically activate
specific complex formations. Because of this, not only does this allow for isolation and

Fully Activated

Partially Actived

Inactive

Figure 3.11 Upright Orientation of Antibody is Desired.

quantification of a multitude of biological markers such antigens, signal proteins,
nucleotides, etc. but also allows for the study of signal transductions in relationship with
the cell‟s microenvironment. Thus, with the rapid development of bioconjugation
techniques, immobilization of antibodies has quickly become integrated with
immunoaffinity chromatography, immunosensors, optical fibers and diagnostic
immunoassays to name a few current applications (61). There are two primary
techniques to immobilize antibodies on a desired surface: direct chemical immobilization
methods which covalently links the IgG on the surface and physical methods of
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immobilization such as adsorption (62). In chemical immobilization, functional groups on
the surface of the desired protein, such as amino and carboxyl groups are targeted.
However, when antibodies are directly adsorbed to solid supports, the specific binding
capacity is usually less than that of a soluble antibody. The primary reason for this
reduced activity is that the random orientation of the antibodies on surfaces, masking
some of the antigen binding sites (figure 3.11). In fact, conventional direct adsorption of
antibodies can potentially denature and reduce proteomic functional sites by more than
90%, as seen in figure 3.11. A common strategy to covalently immobilize antibodies on
surfaces utilizes the free amines of lysine residues. Unfortunately, this approach also
results in random antibody orientation because numerous lysines are present in
antibodies (63). This can inevitably lead to low detection sensitivity and signal-to-noise
ratio, which are two factors that must be avoided in this research. Antibodies are
considered properly oriented and completely active when immobilized by the Fc fragment
since this allows the Fab fragments, or biologically active regions, to be sterically
unrestricted and hence able to maximally bind antigens. Thus the key in immobilization
of antibodies to recruit target proteins is the proper upward orientation of the active Fab
segments (61-64). With the advances in molecular self-assembly techniques and the
knowledge of reagents with strong affinity to Fc recruitment, a methodology shift in
orienting antibodies has occurred in the past ten years from direct to chemical
adsorption. Today, protein A and protein G are commonly employed as tools to bind the
Fc domain of antibodies, with affinities that vary with species and immunoglobulin type.
However, they provide a tool that can ensure sterically unrestricted binding to antigens
via upright orientation (54,62). In the following sections, the affinities of protein A and
protein G binding to Fc regions in antibodies are explored. There will also be a
discussion about the homobifunctional crosslinking chemistry that are employed in
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tethering protein A/G. Two separate methods to immobilize protein A/G and the capture
antibody are used on the 3-APTMS and ODMS test substrates.

3.3.1 Protein A/G
Protein A was first used 1978 to bind to an antibody whereas almost a decade
later in 1989, protein G was similarly used to link to a target antibody. Since that time,
both proteins have both been demonstrated to be powerful affinity ligands to recruit, or
purify specific antibodies because of their high specificity to bind Fc regions of IgGs (65,
66). Today, these proteins are included when oriented immobilization of an IgG is
needed in bioengineering, biochemistry, medical studies and organic chemistry. The
protein A molecule contains four high-affinity (Ka = 108/ mole) binding sites capable of
interacting with the Fc regions from IgGs of several species including human and rabbit.
Optimal binding occurs at pH 8.2, although binding is also good at neutral, physiological
conditions (pH 7.0-7.6). The disadvantage of protein A lies in the fact that only certain
subclasses of immunoglobulins are able to be recruited (67). In comparison, protein G
binds with significantly greater capacity than protein A to several IgG subclasses such as
human IgG3, mouse IgG and rat IgG. Differences in binding characteristics between
protein A and protein G may be elucidated by the dissimilar compositions in the Fc
binding sites of each protein. The tertiary structures of these proteins are very similar,
however their amino acid compositions significantly differ which contributes to their
different affinities (62,68).
Recombinant fusion of the Fc-binding domains of protein A and protein G has
resulted in production of a functionally chimeric protein A/G with broader binding than
either of its primary constituents alone. Binding is less pH-dependent than both protein
A and protein G occurring efficiently at pH 5-8. The enhanced Fc-binding properties of
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protein A/G make it a popular tool in the investigation and purification of antibodies.
Since protein A/G binds to all human IgG subclasses, IgA, IgE, IgM and to a lesser
extent IgD it is an excellent tool for detection of mouse monoclonal antibodies from IgG
subclasses without interference from these other serum proteins. Individual subclasses
of mouse and rabbit monoclonal antibodies are most likely to have stronger affinity to
this chimeric protein than to either protein A or protein G (69).
It should be noted that interactions of enzymes and amino acid in vivo occur at
hydrophobic interfaces (51,59). A combination of this and contact angle data which
indicated that adsorbtion of protein A/G on the hydrophobic silane occurs, allows for the
conclusion that recruitment of protein A/G can be directly linked to hydrophobic SAMs.
This facile assembly will be discussed at greater lengths in the next chapter.

3.3.2 Amine-Reactive Homobifunctional Crosslinkers
A homobifunctional crosslinker can be described as any reagent which has the
capability of covalent linkage between amine-containing molecules (48). When a
complex has two, identical amine-reactive groups it is called homobifunctional and the
two specific crosslinkers used in this research are GA and BS(PEG)5. GA can be present in at least 13 different homologous forms and all demonstrate the ability to network
proteins, leading to an extensive range of possible bioconjugates. The crosslinking of
proteins, either to an inorganic substrate or between protein molecules, involves lysine
residues of the ε-amino group. All of these forms of GA might be reactive toward lysine
residues of proteins and this unique characteristic is why GA is considered one of the
most effective amine-reactive crosslinking reagents (70). In the first test-assembly, GA
is covalently linked to the surface since it is amine-reactive and successively recruits
protein A/G‟s lysine residue (48). BS(PEG)5 is a PEGylation reagent with reactive ends
of N-hydroxysuccinimide, or simply NHS esters. These NHS esters react specifically
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with lysine and N-terminal amino groups at pH 7-9 to form stable amide bonds (71).
Because BS(PEG)5 can double as both an amine-reactive crosslinker as well as a
PEGylation reagent, this versatile reagent is employed in the second and third
assemblies to immobilize protein A/G as well maintain non-fouling surfaces. A great
deal more about the characteristics of non-fouling surfaces will be discussed in section
3.4. Because of the lack of a target amine groups in the ODMS structure, it should be
noted that the amine-reactive crosslinking reagents can only be applied on the 3-APTMS
based substrates.

3.3.3 Methods and Materials: Protein A/G, GA and Capture Antibody
Since GA is a reactive crosslinker in the presence of an amine group, it will be
directly adsorbed onto one of the three experimental samples which possess the
hydrophilic silane (substrate 1). The other two will employ the BS(PEG)5 as a
crosslinker while using it as a primary surface-blocking polymer brush (substrate 2) and
a secondary surface block (substrate 3). The assemblies of these two surfaces will
begin with the adsorption of BS(PEG)5, subsequent to the silanization, followed by the
attachment of protein A/G to immobilize the primary polyclonal antibody. The ODMS,
with an active methyl-monolayer, will be subject to direct adsorption of protein A/G
mimicking native hydrophobic interactions amongst proteins, as mentioned before.
Gluteraldehyde was purchased from Fisher Scientific (product number G151).
The known amine, cross linking reagent can be diluted in ethanol to a working
percentage of 5% weight/volume. (If the stock solution of GA is at 25% concentration: to
prepare 25 ml, 5 ml of GA must be combined with 20 ml of solvent). However to ensure
maximum amine linkage of the amino-silane, a physiological pH of 7.4 is desired (48).
To raise the pH levels of the GA solution a few drops of 1 N sodium hydroxide should be
adequate. 1 normal (N) solution of sodium hydroxide can be understood as the
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molecular weight, 40 grams, in 1 liter of distilled water. The sodium hydroxide was
obtained from Fisher Scientific. Samples were submerged in the solution for a fixed time
of two hours at room temperature. Subsequently, the samples were generously rinsed
with ethanol and blow dried with N2.
Pierce Recombinant Protein A/G (product number 21186) was first made into a
stock solution with a concentration of 1M (1 mg/ml). The solution was made by combining
the vial of protein A/G, 5mg, with 2.5 ml of glycine and 2.5 ml of Delbecco‟s Phosphate
Buffer Solution (DPBS). Both the glycine and DPBS were purchased from Invitrogen.
Since the total volume of stock 1 M Protein A/G is 5 ml, ten aliquots of 500 µl were
portioned and stored at -20 C to maximize longevity of the mixture. A working solution
of 1 mM (1 µg /ml) was then prepared by diluting the stock solution in DPBS. For
example, 10 µl of stock Protein A/G was diluted in 10 ml of DPBS. Substrates were
incubated in the solution for a fixed time of 15 minutes at room temperature. Afterwards
the substrates were thoroughly rinsed with and stored, if needed, in DPBS at 4° C.
The polyclonal anti-bcl-2 IgG derived from rabbit was purchased from Sigma
Aldrich (product number PRS3337) at a concentration of 1 mg/ml. The initial antibody was
aliquot into ten equal portions of 10 µl and stored at -20° C to ensure longevity. Upon
use, the antibody needed to reach a working concentration of 5 ug/ml in DPBS (as
suggested by Sigma-Aldrich). For antibody immobilization on each substrate, 50 µl of
working solution, for example if 30 samples are desired: 1500 µl of DPBS and 7.5 µl of
stock. To apply the antibody on one side of the glass substrate 50 µl of the working
solution is placed on parafilm (purchased from Cole Parmer). Because of the hydrophilic
properties of the film the solution agglomerates. Slides should be carefully deposited on
top of the drop of solution for a fixed time of an hour at room temperature. Afterwards,
the slides should be thoroughly rinsed in DPBS.
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3.4

PEGylation Reagents for Protein Resistant Surfaces
A primary concern for this research is functionalizing non-fouling properties onto

bioconjugated surfaces. A non-fouling, or protein-resisting surface is a key characteristic
of many biomaterial and bio-nanotechnological surfaces (72). In assays looking to
recruit analyte proteomic markers from urine or serum samples it must be certain that
there is minimal non-specific binding with other proteomic molecules which would bias
the data. In a diagnostic setting, the threat of false-positive results has provided a great
deal of motivation to study a multitude of non-fouling surface techniques in a wide variety
of fields. The most common approach to reduce protein adsorption on a surface is via a
coating of poly(ethylene glycol) (PEG) chains. Studies over the last few decades have
shown that surface modification with long-chain PEG chains (about 2,000 Daltons and
above) can drastically reduce protein adsorption (52,55,72). As a result, a number of
methods to immobilize PEG-layers onto surfaces have been developed that include
physisorbtion and covalent linkaging onto the surface of interest. The large majority
involve the deposition of the PEG layers onto a surface from solution (73). Aminereactive PEGylation reagents have become very popular to for a variety of protein
modifications including tethering of proteins and in this case recruitment of protein A/G.
As mentioned in section 3.3.2, BS(PEG)5 is a PEGylation reagent terminated on both
sides with amine-reactive NHS esters allowing for protein crosslinking. On the
otherhand, MS(PEG)4 can be considered a unifunctional PEGylation reagent with
reactive NHS esters one end of a PEG chain (figure 3.12). The third PEGylation reagent
that was used was a tri-block copolymer named Pluronic F127. Pluronic, as seen in
figure 3.12 below, contains a central hydrophobic poly(propylene-oxide) (PPO) chain
surrounded by two PEG chains (note: for over 50 repeat units of ethylene oxide termed
PEG, otherwise PEO). Intuitively, the protein resistance is directly dependent on the

62

adsorbed amount of Pluronic, and since the PPO is responsible to immobilization onto
the surface anything greater than 30 chains have been shown to be easily linked onto
hydrophobic surfaces (52). A large number of Pluronic species exist with the initial
letters corresponding to the physical state and subsequent numbers defining the weights
of the PPO and PEG chains. Pluronic F127 contains 56 repeat units of PPO flanked by
two 101 repeat units of PEG. It has been clinically demonstrated that surfactants with
longer PEG chains will be better at resisting proteins, if they can be successfully
adsorbed on the surface (74). The Pluronic reagent is important in this study because it
indirectly measures the efficacy of adsorbed PPO chains versus covalent amine-reactive
NHS esters, to immobilize PEG chains. The purpose of including a variety of
PEGylation reagents is to arrive at the reagent which not only powerfully attaches to the
surface but can also disperses the thickest PEG brush on the test substrates.

Figure 3.12 Pluronic and MS(PEG)4 Structure. (75)
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3.4.1 Methods and Materials: BS(PEG)5, MS(PEG)4 and Pluronic
For all of the experimental substrates, the PEGylation reagents were adsorbed
after the introduction of the primary antibody, at the end of the surface assembly
protocol. The only discrepancy is for substrate 3 which contains both the BS(PEG)5, after
the silanization, and similarly ended with MS(PEG)4. The functionalized hydrophobic
surfaces employed Pluronic for substrate 5 and MS(PEG)4 in substrate 4. Although
greater capture would inevitably have been seen with adsorption of the analyte bcl-2
standard directly after the primary antibody, the research looked to emulate the
technique the functionalized surface would implement within a diagnostic device, which
would need to introduce the analyte subsequent to full assembly.
MS(PEG)4 was purchased from Thermo Scientific (product number 22341) and
must first be made into a stock solution at a concentration of 250 mM. This was
accomplished by mixing 1100 µl of dimethyl sulfoxide (DMSO), or any other polar aprotic
solvent, with the 100 mg vial of MS(PEG)4 to create a stock solution. The solution was
then aliquot into 10 equal vials of 120 µl and stored at -20° C to ensure longevity. Upon
use, a solution of 1mM in DPBS was used (as prescribed by the manufacturer). For
example in 20ml of DPBS 80 µl is needed. Substrates were deposited in the solution for
a fixed time of 15 minutes at room temperature. Afterward, the samples were liberally
rinsed with DPBS. Samples were stored in DPBS at 4° C if necessary.
BS(PEG)5 was purchased from Thermo Scientific (product number 21581). A
stock solution must first be prepared combining the 100mg mass of the BS(PEG)5 with
650 µL of DMSO. The 250 mM stock solution was then aliquot into seven vials of 100
µL and stored at -20° C. Upon use, a solution of 1mM in DPBS was required (as
prescribed by the manufacturer). For example in 20ml of DPBS 80 µl of BS(PEG)5 is
needed. Substrates were deposited in the solution for a fixed time of 15 minutes at room
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temperature. Afterward, the samples were liberally rinsed with DPBs. Glass slips were
stored in DPBS at 4° C if necessary.
Pluronic F-127 was purchased from Sigma Aldrich (product number P2443).
F127 implies 3600g/mol molecular weight of the central poly(propylene glycol) and 70%
polyethylene glycol chains content. The letter „F‟ infers its solid nature and to create a
working solution it was diluted in deionized water to 1% weight/volume (55). The Pluronic
solution was given 12 hours to settle and the slides were incubated for a fixed time of an
hour at room temperature for both procedures.
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CHAPTER 4: NOVEL ELISA TO ASSESS EFFICACY OF BCL-2 CAPTURE
4.1

Sandwich ELISA Technique
After an understanding regarding the various bcl-2 test surfaces has been

established and the bioconjugation reagents have been chosen, the method for testing
the analyte capture will be fully revealed. In this chapter, the intricacies of bcl-2 standard
recruitment, quantification and selection of the best test substrates are all clarified.
Once the most suitable surface was identified a serial dilution of bcl-2 concentrations not
only confirmed the overall sensitivity of the bioconjugated surface, but also allowed for
comparison against published concentration of early stage and late stage ovarian
cancer. Therefore, an ovarian diagnostic testing platform is revealed in this chapter.
The overall capture cannot simply be measured in a one-step quantification
process. Rather novel assay protocols must be established to test the efficacies of
these substrates. ELISA, or enzyme-linked immunosorbent assays have long been
employed in clinical settings in a wide variety of fields to be a diagnostic tool in
measuring the presence or concentration of an analyte in a complex solution (76).
Though today some ELISA protocols might not necessarily be „enzyme-linked‟ the
general principles and techniques are similar and thus can be grouped into the same
broad category as ELISAs. Before the development of ELISA techniques the only real
option for conducting an immunoassay was through radioactively-labeled target
antibodies. Quantifications for radioimmunoassays are somewhat accurate; however
they pose a potential health risk. In 1971, a safer alternative was published by
researchers at Stockholm University in Sweden which employed the knowledge of
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discrete antibodies to recruit analytes which could be enzymatically traced through
signals. A common signal is an enzymatically responsible change in color in the
presence of clinically tested receptor-ligand bindings (76). Because of the multitude of
receptor-ligand interactions in vivo, the ELISA method was quickly employed for in vitro
analysis of concentrations of analytes in all life science and engineering fields.
Performing an ELISA involves at least one capture antibody which has affinity for a
particular proteomic target. Briefly, a complex solution with an unknown concentration of
an analyte is exposed to a detection antibody. A secondary antibody, which has affinity
for the detection antibody as well as an enzyme, then converts the substrate into a
visible signal thus indicating a quantifiable reading of the concentration of the analyte
(77). A more comprehensive „sandwich ELISA‟ method is employed in this research to
assess the bcl-2 capture on the substrate and can be seen in figure 4.1.

Figure 4.1: Sandwich ELISA Quantification Process.

In the novel sandwich ELISA method employed in the research, the idea was to
quantify the bcl-2 concentrations immobilized by the capture polyclonal antibody (dark
blue) by analyzing the levels of targeted mouse monoclonal anti-bcl2 (light blue) and
alkaline phosphatase IgG (green) levels. Finally, an enzymatic reaction, mediated by

67

the secondary detection antibody (in green) converts the substrates to a product with
unique optical properties which can then be measured at a specific wavelength by any
plate reader with spectrometer capabilities.
The analyte in this assay is a recombinant bcl-2 protein standard which was
purchased from R & D systems. Though natural bcl-2 contains a carboxyl-terminal,
mitochondria targeting sequence not present in the recombinant bcl-2: both are able to
maintain the ability to neutralize their fellow pro-apoptotic bcl-2 family members (78).
Therefore for the research at hand, the recombinant bcl-2 is functionally identical to the
anti-apoptotic protein that is elevated in ovarian cancer. The primary detection antibody
is a mouse antibody which targets one site on the bcl-2 protein and was purchased from
Santa Cruz Biotechnologies to initiate the novel ELISA protocol (79). The enzymatic
antibody that was used was an alkaline-phosphatase IgG which was obtained from
Jackson Immunology. The para-Nitrophenylphoshate (pNPP) liquid which turns yellow in
the presence of the alkaline phosphatase enzyme was purchased from Sigma-Aldrich.
When in the presence of alkaline phosphatase IgG, phosphoric acid (H3PO4) and the
important para-Nitrophenol (C6H5NO3) a soluble end-product is produced. This paraNitrophenol is reason for the yellow color in the reaction, allowing measurements at 405
nm which corresponds to the yellow wavelength. This then revealed the concentrations
of analyte on the substrate. Ideally, only the detection of bcl-2 should be measured

Alkaline Phosphatase

Figure 4.2 Enzymatic Alkaline Phosphatase Reaction.
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by the specific, direct binding to the antibody on the surface. However, often indirect
interactions or non-specific binding occurs on the surface by competitive receptor-ligand
binding. It is a challenge in any ELISA protocol to avoid inflation of the data that occurs
because of non-specific binding. This non-specific binding that potentially occurs is
often referred to as background and in a diagnostic setting it is vital to minimize
background. The ELISAs were able to be executed with and without the presence of the
analyte of the non-specific interactions could be quantified on each surface.
The BioTek Synergy HT plate reader was used to read the output yellow color at
405nm through endpoint analysis. When absorbance measurements are made, the
instrument switches to a Xenon Flash Lamp and a monochromator for wavelength
selection. The use of a xenon flash lamp allows for both UV and visible light absorbance
measurements. The monochromator provides wavelength selection from 200 to 999 nm
in 1 nm increments and offers repeatability of 0.03% and reads a 96-well plate in 14
seconds (80). The output units of the reading are expressed in optical density of relative
absorbance units (AU). The governing equation that is employed by the device to
provide a reading follows.

Absorbance Units405nm= log10 (Io/I)

(1)

When the intensity of the light before it enters the sample is divided by the
intensity of the light at a specific wavelength, in this case 405 nm, the transmittance of a
sample can be found. Taking the log10 of the transmittance the relative AU can then be
found. As far as the logarithmic AU scale is concerned: a reading of 1 can be
understood as the ten-fold reduction in optical light density and a reading of 3 is a
thousand-fold reduction in optical light density (81). This method of analysis is
commonly used in ELISA because of the ease of operation of a monochromator and the.
In this way, specific absorbance readings are statistically relevant when comparing and
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contrasting them to one another. This is to say that each plate that is read, allows for
comparison of measurements with each other. Each plate that is read, therefore, cannot
be compared to one another as there could potentially be discrepancies in the readings.
For example a higher sensitivity can be expected from readings of a 96-well plate than
that of a 24-well plate by potential gradients that can form in a 24-well plate.
Accordingly, each reading by the plate reader was analyzed and expressed in later
absorbance plate readings by subsequent manipulations of the test substrates.
Therefore the novel sandwich ELISA method was used to test a multitude of surface
assemblies until the substrate with highest absorbance and lowest background was
conclusively found. This novel surface-assembly which displayed capture with the
highest efficacy can be considered a facile bioconjugation technique for developing a
testing platform for an ovarian cancer diagnostic device.

4.2

Methods and Materials of ELISA
The novel sandwich ELISA was performed in three primary steps: capture of the

bcl-2 standard protein, binding of the primary and secondary detection antibodies and
the enzymatic reaction following the introduction of the liquid pNpp substrate to produce
a soluble yellow end product.
Recombinant Human Bcl-2 Standard: This protein was obtained was from R & D
Systems (product number 827-BC) at a concentration of 306.6 ug/ml. The protein was
aliquot into twelve equal portions of 15 µl and stored at -20° C to ensure longevity. Upon
use, a working concentration of 0.1 ug/ml in DPBS was used (6). To apply the protein on
one side of the glass substrate, 50 µl of the working solution is placed on parafilm.
Slides should be carefully deposited on top of the drop of solution for a fixed time of an
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hour at room temperature. Afterwards, the slides should be thoroughly rinsed and
stored if needed at 4° C in DPBS if necessary.
Bcl-2 (8c8) Monoclonal Antibody: This antibody derived from mouse was
purchased from Santa Cruz (product number SC65392) at a concentration of 0.2 mg/ml.
The initial antibody was aliquot into ten equal portions of 10 µl and stored at -20° C to
ensure longevity. Upon use, the antibody needed to reach a working concentration of 1
ug

/ml in DPBS. For antibody adsorption on each substrate, 50 µl of working solution is

needed for example if 30 samples are desired: 1500 µl of DPBS and 7.5 µl of stock. To
apply the antibody on one side of the glass substrate, 50 µl of the working solution is
placed on parafilm for a fixed time of an hour at room temperature. Afterwards, the
slides should be thoroughly rinsed and stored if needed at 4° C in DPBS.
X-mouse Alkaline Phosphatase IgG and pNPP substrate: This antibody was
obtained from Jackson Immunology (product code 200-052-037) and aliquot at -20oC at
a concentration of 0.3 mg/ml. Upon use, the antibody needed to reach a working
concentration of 0.3 ug/ml in DPBS. For antibody adsorption on each substrate, 50 µl of
working solution is placed on parafilm for a fixed time of an hour at room temperature.
Afterwards, the slides should be thoroughly rinsed with DPBS and deposited carefully
into a standard 24 well plate. Para-Nitrophenylphoshate (pNPP) substrate was
purchased from Sigma-Aldrich (product number P7988) and 250 µl was added in each
well. Slowly over the next thirty minutes a soluble yellow end product appears in each
well, as seen below. Adding 62.5 µl of 3M NaOH quenches the reaction and either 200
µl of each sample can be transferred to a 96-well plate or plates can be directly read in
the 24-well plate. The yellow end product can be seen in figure 4.3 on the following page
in both 96 and 24-well plates.
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Figure 4.3 Novel ELISA Read in 96-Well and 24-Well Plates.

4.3

Bcl-2 Quantification
Each of the assemblies shown in table 3.1 on page 41 were tested for the

specific recruitment of the bcl-2 standard analyte. The five substrates were compared
with and without analyte and the results can be seen below in figure 4.4, with the signalto-noise ratio being shown. Two trends were desired to be seen in data. Firstly, high
overall signal with the presence of analyte (corresponding to sensitivity) and high signalto-noise ratio (corresponding to specificity). Note the units are in relative AU for this
chapter.
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Relative AbsorbanceUnits (AU)

0.70

Absorbance Readings of the 5
Test Substrates
0.97
with bcl-2
without bcl-2

0.60

1.15

0.50
0.40

1.50

0.30

1.16

0.74

0.20
0.10
0.00

1

2

3

4

5

Test Substrate Number
Figure 4.4 Absorbance Readings of the 5 Test Substrates.

It can be seen that the substrate 1 showed the highest absorbance with or
without the presence of the analyte on the substrate, roughly 75% more than substrate
2, almost four times that of substrate 3 and 4 and two and a half times more than
substrate 5. However, substrate 5 was the only assembly where a favorable signal-tonoise ratio could be seen (approximately 1.5). After the initial trial it could be surmised
that this surface had the highest capture efficacy. Although substrate 1 displayed the
highest relative absorbance, the signal-to-background ratio was low and therefore
indicated poor specificity for bcl-2. As a result substrate 5 showed the highest capture
efficacy. Surface 3 and 4 resulted in the overall lowest readings from the initial ELISA
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and because of statistically significantly lower capture (almost half of the other surfaces),
they were eliminated as test substrates for bcl-2 recruitment in the following trials.
Some preliminary conjectures can be made about the bioconjugation reagent
effectiveness after the initial reading. Substrates 2 and 3 are very similar with the
additional covalent linkaging of the MS(PEG)4 in substrate 3 being the only difference.
Attachment of both amine-reactive PEGylation reagents greatly suppressed the overall
signal with and without the analyte, thus not offering the sensitivity that is desired in this
research. It can therefore be concluded that an excess amount of PEGylation reagents
on surface 3 obstructs the recruitment of the analyte bcl-2 as well as the capture and
detection antibodies. Substrates 4 and 5 are similar with the only difference being the
PEGylation reagent being used, MS(PEG)4 and Pluronic respectively. Substrate 5
displays twice as much signal-to-noise than substrate 4, (0.74 vs. 1.50), confirming that
Pluronic is a highly suitable at maintaining a non-fouling surface on a hydrophobic selfassembled monolayer (SAM,) such as the ODMS based surfaces. It can therefore be
concluded that substrate 3 and 4 are incapable of diagnostically relevant bcl-2 capture,
as seen with the black arrows in figure 4.4.

4.3.1 Fc Region Antibody to Lower Background
Since the majority of the surfaces displaying a large amount of non-specific
binding, a strategy was to be used to counter this problem. Because of the high affinity
of protein A/G for Fc regions of antibodies, conceivably the primary detection and
alkaline phosphatase antibodies could be recruited by vacant A/G on the testassemblies, biasing the overall signal. Thus, a recombinant Human IgG1 Fc portion was
obtained from R & D systems (catalog number 110-HG) to be adsorbed onto the
substrates before attachment of the secondary ELISA antibodies to occupy any
unoccupied protein A/G sites. These Fc regions were diluted in DPBS to an active
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concentration of 0.5 µg/ml and applied on the surface using the parafilm technique that
was employed for the other antibodies. It should be noted that this is the first research
which employed the novel use of Fc portions to address high non-specific binding
contributing to background. In the following data, the presence of bcl-2 as well as the
presence of Fc regions were varied and tested for the three remaining test surfaces:
substrates 1,2 and 5. The results can be seen below in table 4.1.

Table 4.1 Fc Antibodies: Do Not Lower Non-Specific Binding.
substrate

With

BCL2

substrate

With

BCL2

substrate

With

BCL2

1

with Fc
0.56

no Fc
0.36

2

with Fc
0.48

no Fc
0.37

5

with Fc
0.78

no Fc
0.54

0.44

0.67

0.58

0.46

0.43

0.36

0.22

0.96

0.44

0.28

0.40

0.44

0.39

0.60

0.39

0.46

0.38

0.22

avg

0.40

0.65

avg

0.47

0.39

avg

0.50

0.39

std

0.14

0.24

std

0.08

0.08

std

0.19

0.14

substrate

No

BCL2

substrate

No

BCL2

substrate

No

BCL2

1

with Fc
0.41

no Fc
0.67

2

with Fc
0.66

no Fc
0.44

5

with Fc
0.17

no Fc
0.23

0.54

0.35

0.51

0.31

0.24

0.25

1.10

0.59

0.56

0.48

0.35

0.33

avg

0.39
0.61

0.77
0.59

avg

0.52
0.56

0.52
0.44

avg

0.40
0.29

0.11
0.23

std

0.33

0.18

std

0.07

0.09

std

0.10

0.09

In the test substrates with the presence of bcl-2 standard the introduction of the
Fc portions caused a decrease in relative AU of 37.73% for substrate1 and a surprising
increase of 20.5% and 28.2% for substrate 2 and 5, respectively. Without the presence
of the analyte, however an opposite trend was seen for substrate 1, indicating
statistically irrelevant changes in signal with or without the Fc regions on the surface.
Substrate 2 displays no real correlation with or without the analyte and thus the 3-
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APTMS based assemblies failed to improve the signal-to-noise ratios. Substrate 5
displayed a 70% increase in signal in the presence of the analyte, with or without the Fc
portions, confirming that the reagent was unable to decrease background. In fact, none
of the test surfaces displayed significantly higher signal-to-noise ratios with the
application of the Fc portions. Substrate 1 actually decreased in signal-to-noise with Fc
regions compared to without (1.09 vs. 0.65) with a similar trend being seen in substrate
2 as well (0.90 vs. 0.84). Substrate 5 displayed a small increase in signal-to-noise ratio
with the introduction of Fc portions, 1.72 vs. 1.70, however because the increase was so
small (about 1%), it is deemed statistically irrelevant. It is worth mentioning, that with or
without the Fc portions the most efficient bcl-2 capture continued to occur on assembly 5
above all other substrates. This was assessed by the surfaces ability to display
adequate sensitivity and superior specificity towards the bcl-2 protein. That being said, it
can be concluded that the Fc regions did not contribute to improving of the capture
efficacy of the surfaces.

4.3.2 Analysis on Orientation of Capture Antibody
Molecular self-assemblies‟ variability leads to the presence of „defect‟ that occur
on bioconjugated surfaces. Each ELISA trial revealed valuable information commenting
on the ability of the reagent to link on the substrates. A key point of interest was low
variability in the assemblies to ensure reproducibility of the technique. Both substrate 1
and 2 having low signal-to-noise ratio and marked inconsistencies in overall signal (high
standard deviations), failed to display reproducible, specific capture Because of the fact
that the substrate 1 consistently displayed highest overall signal, substrate 2 was
eliminated from subsequent ELISA trials. The high degree of 3-APTMS polymerization
onto hydroxylated substrates led to high variability in the initial monolayers that formed
(57), undoubtedly affecting the immobilization of subsequent reagents.
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To arrive at a surface that would be best for bcl-2 capture with the highest
efficiency, substrates 1 and 5 were further assessed. A „scaled down‟ approach was
used to assess the efficiency of both surfaces to successfully bind protein A/G therefore
immobilizing the capture antibody. Thus, the GA-protein A/G step in substrate 1 and the
direct adsorption of A/G in substrate 5 were tested. By modifying these crosslinking
reagents inclusion in the functionalization process, a better understanding on the
individual contributions of GA and protein A/G on the recruitment of the analyte and
could be arrived at. This ELISA was conducted looking to maximize the sensitivity of the
substrates towards the bcl-2 protein. The test assemblies are listed in figure 4.5 and the
results for substrates 1 and 5 can be seen in figures 4.6 and 4.7 respectively.

1a: 3-APTMS

GA

1b: 3-APTMS

protein A/G

1c: 3-APTMS

GA

1d: 3-APTMS

protein A/G

capture anti-bcl2

capture anti-bcl2

capture anti-bcl2

capture anti-bcl2

5a: ODMS

protein A/G

5b: ODMS

capture anti-bcl2

MS(PEG)4

MS(PEG)4

MS(PEG)4

MS(PEG)4

capture anti-bcl2

Pluronic

Pluronic

Figure 4.5 Assessing Maximum Antibody Immobilization on Substrate 1 and 5.
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Substrate 1: Efficacy of Antibody Orientation
0.7

Relative Absorbance Units

0.6

with bcl-2
without bcl-2

0.5
0.4
0.3
0.2
0.1
0.0

Full Assembly

Without GA

Without A/G

Without GA & A/G

Figure 4.6 Amine-Crosslinking for Antibody Recruitment on Substrate 1.

Substrate 5: Efficacy of Antibody Orientation
with bcl-2

0.4

without bcl-2

Absorbance Units

0.35
0.3
0.25
0.2
0.15
0.1
0.05
0

Without A/G

Full Assembly

Figure 4.7 Amine-Crosslinking for Antibody Recruitment on Substrate 5.
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When analyzing if improvements in sensitivity for bcl-2 were made, it was seen
that for substrate 1, the full assembly and without protein A/G displayed highest overall
absorbance. However, a statistically relevant increase in signal is not achieved with only
GA and therefore one surface cannot be deemed more suitable for sensitive bcl-2
capture than the other. When addressing direct adsorption of protein A/G on the 3APTMS (substrates 1b and 1d) it was seen that the maximum capture was similar with
or without the presence of protein A/G (0.33 vs. 0.28, respectively). This perhaps
indicated that the need for an amine-crosslinker, such as GA, on a 3-APTMS SAM for
antibody tethering was crucial. Thus, the full assembly of substrate 1 was demonstrated
a highly sensitive but insufficiently specific capture of bcl-2, and could not be improved
upon. However, for substrate 5, it can be seen that the highest signal and best overall
signal-to-noise ratio (1.412) was seen with the full assembly. Without adsorbing protein
A/G onto the surface, a statistically significant decrease in the overall signal and capture
efficacy was seen (signal to noise ratio of 0.824). Thus, protein A/G attachment onto the
hydrophobic silane is an efficient method to immobilize target antibodies.

4.3.3 Selection of „Best‟ Bioconjugated Surface
Substrate 1 lacks in the two major parameters which are important in this
research. First, the surface continually fails to specifically quantify the bcl-2 capture,
being biased by the presence of other non-specific interactions. Second, the surface
fails to show the reliability and consistency needed to be diagnostically relevant. In fact,
the standard deviation is 250% percent lower in the ODMS based substrate 5 (0.06 vs.
0.138) demonstrating that although 3-APTMS SAMs were built-up and widespread, they
are not as reproducible as the hydrophobic, ODMS surfaces. Substrate 5 consistently
displayed favorable overall signal and signal-to-noise ratio. This facile assembly can
therefore be selected as the best substrate for efficient capture of the bcl-2 analyte.
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4.4

Diagnostically Relevant Bcl-2 Capture on Substrate 5
To ensure that the proper surface was selected further novel ELISA testing must

be done to verify the decision. Again, two paramount features of an ideal substrate are
efficient immobilization of the primary antibody and prevention of non-specific binding.
For substrate 5 the two reagents which directly regulated these interactions are protein
A/G and Pluronic. By varying these two reagents, with and without the presence of the
analyte (as seen in the tree diagram below), a comprehensive analysis can be
conducted quantifying the impacts of these important reagents on recruiting antibodies
and preventing unwanted binding, respectively. Likewise, if a better functionalization
assembly is found, that can be assessed as well.

Chlorosilane

+ Protein A/G

+ Pluronic

+ Bcl-2

- Bcl-2

- Protein A/G

- Pluronic

+ Bcl-2

+ Pluronic

- Bcl-2

+ Bcl-2

- Bcl-2

-Pluronic

+Bcl-2

- Bcl-2

Figure 4.8 Analysis on Protein A/G and Pluronic Immobilization on Substrate 5.

Before presenting the results it should be noted of a couple of modifications in
the ELISA method that were made at this juncture in the research. All of the initial
readings discussed were read in a 24-well plate. As mentioned, the output of a plate
reader can be compared to readings across one individual plate. It was noted that there
was an increase in signal from a 96-well plate compared to the of a 24-well plate,
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however the relative differences were similar. Additionally, a known surfactant called
Tween-20 (Sigma-Aldrich, product number P2287) was employed as a washing agent in
the ELISA steps of the detection antibody and enzymatic antibody. Adding this reagent,
at a concentration of 0.05% in a common phosphate buffer solution, helps to prevent
non-specific antibody binding in immunosorbent assays (82). The results of the assay
follow. Note, the signal-to-noise ratios are displayed above the graphs.

1.8

Substrate 5: Assessment Capture Efficacy
1.22

Relative Absorbance Units

1.6

with bcl2

1.4

without bcl2
1.2

1.89

1.0

1.52
0.8

1.27
0.6
0.4
0.2
0.0

Full Assembly

Without Pluronic

Without A/G

Without Both

Figure 4.9 Substrate 5: Displays Superior Selectivity and Specificity of Bcl-2.

Analysis of the results reveals some valuable information. The noticeable
increase in signal-to-noise will be credited to the tween 20 reagent used in the dilution
and rinse step, which aims at reducing non-specific binding. To assess the crosslinking
efficiency of substrates with protein A/G to the ones without, (substrates 5a and 5b vs.
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substrates 5c and 5d), a 76% increase in signal was seen (1.27 vs. 0.76, respectively).
Substrate 5b (with no Pluronic) resulted in a marked increase in signal, both with and
without the presence of the analyte when compared to substrate 5d (with neither
Pluronic nor A/G). Therefore because of the direct correlation between protein A/G and
increased signal, it was concluded that the direct adsorption of protein A/G on a
hydrophobic surface is a viable technique to orient desired antibodies. To assess
Pluronic‟s effectiveness the comparison of the full assembly (5a) to the assembly only
missing the PEGylation reagent (5b) reveals a 43% increase with and a 122% increase
without the presence of the bcl-2 analyte, respectively. Coupling this with the overall
lowest signal-to-noise ratio of the full assembly of substrate 5 (1.89), we can safely
conclude that the Pluronic reagent maintains a non-fouling surface on the substrate.
Certainly it can be concluded from this data that protein A/G is effective at orienting the
capture antibody and that Pluronic limits non-specific interactions on the hydrophobic,
ODMS based assembly. Because of this and the facile functionalization method,
substrate 5 is further validated as the best overall choice for the capture of the bcl-2
biomarker protein, which corresponds to early stage ovarian cancer.
Although the „best‟ substrate of those tested has been elucidated, to ensure
future nanosensor integration endeavors of this research the surface must display
extremely sensitive capture of bcl-2 level. Up until this point, the concentrations of the
bcl-2 concentrations were held constant at 100 ng/ml. Referring back to Dr. Kruk‟s
findings, levels of bcl-2 in early and late stage ovarian cancer were found to be 2.60 and
3.58 ng/ml respectively. In addition, it was seen that healthy levels of bcl-2 are 0.59 ng/ml
(6). Thus, application of the analyte at the concentrations that were previously executed
(100 ng/ml) would not guarantee the bioconjugate surface suitable for recognition of
urinary bcl-2 levels. Since it is experimentally verified that mass-loaded nanosensors
possess sensitivity in the order of 0.15 pg/ml (9), early ovarian cancer detection is possible
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if the functionalized surface can, at the very least, recognize bcl-2 levels of 0.1 ng/ml. Six
different concentrations were therefore tested: 100 ng/ml, 10 ng/ml, 1 ng/ml, 0.1 ng/ml, 0.01 ng/ml
and 0 ng/ml. Thus by a ten-fold reduction in concentrations, a logarithmic serial dilution of
bcl-2 levels was done. The results can be seen below in figure 4.10 with the arrow
signifying the bcl-2 concentrations corresponding to early stage ovarian cancer (red) and
the healthy levels (light blue) (6) .

Absorbance Readings of Bcl-2 Dilutions
1.4

1.2

Absprbance Reading

1

0.8

y = 0.1743x + 0.12
R² = 0.9602

0.6

0.4

0.2

0

0

0.01

0.1

1.0

Bcl-2 Concentration (ng/ml)

Figure 4.10 Serial Dilution of Bcl-2.
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100.0

The serial dilutions of the bcl-2 analyte on the substrate revealed absorbance
data that displayed a favorable, linear relationship when assessed. This data was fit to a
first degree regression trendline, which can be seen in the graph above. The coefficient
of determination for the line is 0.9602 signifying a very close linear relationship seen
between the data, which is an indication of the applicability of the ODMS based surface
assembly towards ovarian cancer diagnostics. At the concentrations of interest of 0.1
ng

/ml and and 0.01 ng/ml the capture efficacy can be calculated at 1.72 and 1.52

respectively, ensuring that the majority of the signal that is being measured at those
thresholds were because of the analyte not because of non-specific interactions. The
serial dilution demonstrated that the sensitivity of the substrate to recognize bcl-2 is
done at a level ten times than that needed (0.01 ng/ml). This is extremely important
because recognition at such small concentrations would ensure that elevated and
healthy levels of urinary bcl-2 can both be effectively detected by the bioconjugated
surface. Thus, an assembly of hydrophobic ODMS with direct adsorption of protein A/G
to orient the capture antibody and Pluronic F127 to maintain non-fouling properties:
produces a surface that displayed sufficient sensitivity and specificity to be deemed
diagnostically relevant to recognize levels of the bcl-2 protein. Therefore, this research
has demonstrated that integration of the testing platform with a novel nanosensor can
successfully create an ovarian cancer POC diagnostic device for worldwide
implementation.
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CHAPTER 5: PROJECT SYNOPSIS AND FUTURE CONSIDERATIONS
The research presented in this thesis is the first of its kind to quantify a
confirmed, ovarian cancer biomarker, the bcl-2 protein, on novel bioconjugated
substrates. After identification of applicable target reagents, a series of contact angle
measurements along with published results and expected chemistry outcomes, allowed
for validation of the test assemblies that were chosen. A novel sandwich ELISA method
was then employed to quantify the bcl-2 capture on the substrate, to assess the overall
sensitivity and specificity the test assemblies displayed towards the target analyte.
Progressively, substrates displaying substandard relative absorbance units and signalto-noise ratio were eliminated and the remaining substrates were thoroughly assessed
for the efficacies of the crosslinking of protein A/G to recruit antibodies and for the extent
of PEGylation coverage on the surface. After a series of ELISA trials, the assembly of
ODMS with directly adsorbed protein A/G and Pluronic was identified as the „best test
substrate‟ due to continually superior capture efficacy, reproducibility and ease of
assembly. To examine the diagnostic relevance, a logarithmic serial dilution of bcl-2
analyte concentration was done to test the overall sensitivity of this test surfaces. It was
demonstrated that the sensitivity of the substrate to recognize bcl-2 is done at a level ten
times than that needed (0.01 ng/ml), ensuring that elevated and healthy levels of bcl-2 can
be detected by the bioconjugated surface. Thus, the functionalized surface of
hydrophobic ODMS, protein A/G and Pluronic displays sufficient accuracy and sensitivity
in recognizing levels of the bcl-2 protein, and can therefore be successfully integrated
into an ovarian cancer POC diagnostic device.
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This research opens the door to fabricate an ovarian cancer diagnostic device
which can be employed at the POC worldwide. Since the field of ovarian cancer
diagnostics is nascent in its development, future endeavors should be done to integrate
the surface with a novel transducer or other appropriate nanosensor. Current
nanosensors employ piezoelectric currents which are not only expensive, but are not
biocompatible, because of the presence of lead. Because of integration capability, large
bandwidth and by effectively eliminating the need for a matching layer, the capacitive
machined ultrasonic transducer (CMUT) is often employed for microfabricated biosensor
development. Dr. Rasim Guldiken from University of South Florida has designed a dualelectrode CMUT that has been fabricated and has been experimentally operated to
display mass recognition level up to 0.15 pg/ml : easily sufficient diagnostic
implementation. Since the nanosensors typically use very small amounts of energy in
mass quantification applications, one AAA battery will operate a dual-electrode CMUT
for over 1 million hours, truly providing a cost-effective method to quantify the capture on
the aforementioned testing platform. Consequently, calibrating a suitable nanosensor
such as the dual electrode CMUT with the ODMS based testing platform elucidated in
this thesis will allow for development of a threshold that can be corresponded with
healthy and elevated bcl-2 levels. Achievement of both integration of the substrate with
a novel nanosensor and calibration of the nanosensor to threshold concentrations will
result in the creation of a POC ovarian cancer diagnostic device in the near future.
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Appendix A

Review of POC Tests in Low-Resource Settings

Group A Streptococci, also known as a sore throat, is most commonly of viral
origin. Microbiological assays are needed, as clinical presentation alone does not allow
for dependable distinction between bacterial and viral stimulation. Throat swab culture
on a blood agar plate has long served as the reference criterion. Ever since the 1980s,
several rapid tests have been developed targeting the streptococcus gene, which is a
known sore throat biomarker. Initial assays using agglutination techniques were
improved by enzyme immunoassays and more recently immunochromatographic (lateral
flow) tests. Lateral flow tests can be considered a competitive sandwich ELISA
procedure, as once the surface is exposed to a fluorescent antibody, the analyte protein
can then be measured at a discrete wavelength. Lateral flow tests are upwards of 95%
and cost-effective they enable treatment to be started in the case of a positive test result.
The wide availability of sore throat tests has led to a steady decline in antibiotic
prescriptions and in doing so contributing to avoidance of problem of antibiotic
resistance (1-2).
Malaria continues to be a leading cause of death caused by infections. The poor
prognosis of malaria is largely because the disease displays a clinical presentation that
is markedly erratic, and key symptoms such as fever and chills might be missing in a
substantial percentage of patients. Thus, about 60% of cases are initially misdiagnosed
in North America (3). A diagnostic assay is therefore needed in the setting of the broad
differential diagnosis and the possibility of co-infections that are perhaps overt in their
clinical presentation. Giemsa thick blood smears are still considered to be the reference
standard for malaria diagnosis. Although it is moderately inexpensive in the developed
worlds, accurate diagnosis of malaria necessitates microscopy and consequently related
expertise. Unfortunately, there is a scarcity of adequate microscopes and trained
clinicians in emergency rooms of low resource settings all around the world. In recent
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years rapid diagnostic techniques have been developed in to amerliorate the restrictions.
First introduced in the 90‟s, these lateral flow tests, supply results in less 15 minutes and
have showed encouraging results when validated with microscopic evaluation.
Sensitivity, which varies with the level of parasitaemia (quanitative measure of parasites
in the blood), is usually higher than 90%, and as a matter of fact recent findings indicate
that rapid tests might perform better than microscopy in low resource settings. Even so,
rapid tests cannot produce reliable quantification of antigen amount and so cannot
replace microscopic evaluation for this infectious disease (4).
C. trachomatis is the most common bacterial sexually transmitted disease
worldwide. Molecular amplification tests serve as the diagnostic reference standard
because of their higher sensitivity and better acceptability when performed on urine
samples. That being said, molecular diagnosis remains expensive, and the delay before
results are available implies a second visit for the initiation of treatment. This second
appointment may often be missed in low resource settings, leaving numerous infected
patients untreated. On the other side, the high frequency of erratic infections makes
microbiological diagnosis necessary before empirical therapy. In this setting, a POC test
would have a major impact, allowing patients to receive diagnosis and treatment during
the same consultation (5).
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Review of Selected Proteomic Techniques

Qualitative proteomic assays aim to study changes in protein expression by
monitoring changes in protein mixture composition under various physiologicallyanalogous conditions. Similar to genomics experiments, a standard qualitative
proteomics analysis compares the relative levels of thousands of protein species in
biological samples by prevailing successful protein-profiling technologies: namely 2Dimensional Gel Electrophoresis (2-DE) (1). Two-dimensional gel electrophoresis (2DE)
has been the most widely used means for protein purification or the isolation of a specific
protein from a complex mixture. Proteins are separated along two axes, the first
dimension based on their isoelectric point (magnitude of charge) and the second
dimension based on the respective molecular masses, (via mass spectrometry and the
mass-to-charge ratio). Because of the controlled pH gradient, detection of lower
abundance proteins is possible via high resolution microscopy. Discrepancies between
samples can be compared relatively by quantifying the ratio of spot intensities. Mass
spectrometry (MS) is the top technique for determining masses of particles. Utilizing the
power of MS, advancements in identification of isolated proteins have made 2-DE an
ever more comprehensive option for protein mixture analysis. Some of these MS
advancements, namely time-of-flight (TOF) have brought these two chosen assays to
the forefront of qualitative proteomic analysis:
1) Matrix-Assisted Laser Desorption/Ionization, (MALDI) is an ionization technique
allowing the analysis of biomolecules (like proteins, peptides and sugars) and
large organic molecules (such as polymers, dendrimers, other macromolecules).
A nitrogen laser beam triggers the ionization and MALDI enables the conversion
of biomolecules into a charged gaseous state to be investigated by TOF MS.
MALDI-TOF instruments are typically equipped with an "ion mirror", deflecting
ions with an electric field, thereby increasing the resolution (2)
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2) Surface-enhanced laser desorption/ionization, (SELDI) is a variation of MALDI,
which immobilizes specific antibodies allows for high-throughput screening
because of its versatility, ease of use, low cost and reproducibility. Through the
use of specific biomolecular binding sites, the SELDI platform allows for highly
specific proteomic analysis (in the femtomolar range). Much like MALDI, time-offlight mass spectrometry (TOF-MS), is the most appropriate mass separation
technique used with SELDI. Because of these qualities, SELDI has advantages
over other technologies such as 2DE and enzyme-linked immunosorbent assays
(ELISA) (3).

Quantitative proteomics aims at exposing numerical disparities in protein
concentration within a sample. Quantitative proteomics assays offer all of the
biomolecule identification capabilities as qualitative assays, while including quantification
as an additional advantage. Qualitative proteomic techniques have provided
indispensable knowledge about cancer progression and early biomarker discovery.
While monitoring qualitative changes is imperative, further development of quantitative
tools can provide insight into disease mechanisms (in particular characterization of cell
function, disease mechanism and biomarker discovery), that qualitative proteomic
assays cannot. Recently, enabled by the influx of novel quantitative proteomics
technologies, rapid advancements in global detection and quantitation of proteins have
provided both opportunities and challenges to discover molecular mechanisms of cancer
and other diseases (4). Two prevalent quantitative proteomics methods are illuminated
below.
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1) Stable isotope labeling with amino acids in cell culture, (SILAC) has become a
popular labeling strategy for peptide quantification. It not only provides
quantitative analysis of relative changes in protein abundance from specific cell
treatments, but also of proteins for which there are no antibodies available.
SILAC assays consist of growing cell populations with „light‟ or „heavy‟
nonradioactive isotopes, expressed through standard cellular protein synthesis.
They are grown identical, except that one of them contains a „light‟ and the other
a „heavy‟ form of a particular amino acid. Once equal amounts of proteins from
both cell populations are combined, they are separated using protein purification
techniques, such as 2DE. The proteins are enzymatically digested into smaller
peptides using a protease, such as trypsin. Because of the chemical similarities
of „light‟ and „heavy‟ labeled proteins, they both detected simultaneously and the
relative peak intensities of multiple distinct peptides which are gathered from the
MS analysis can then be manipulated to determine the average change in protein
abundance in the treated sample. SILAC is economical and reproducible and
labeling is virtually 100%, thus marking is as a promising technique that is
currently being extensively applied for biomarker discovery, cell signaling
dynamics, identification of posttranslational modification sites, protein-protein
interaction and cellular proteomics all over the world(5).
2) Isobaric tags for relative and absolute quantification, (iTRAQ) is a robust,
multiplexed quantitative proteomic analysis technique. Labeling of peptides, like
SILAC assays, are employed with a compound that produces isobaric reagents,
or reporter ions, within the sample. Once the proteins are enzymatically digested
through an appropriate protease, current identification and quantification of
multiple samples can be achieved via MS analysis. The key advantage that
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iTRAQ provides is the amine specificity of these reagents, which possess high
affinity to most peptides in the complex, limiting the loss of information from
samples involving post-translational modifications. Applying this technology to
the tandem MS fragmentation data, a low molecular mass reporter ion is
generated that can be used to relatively quantify specific proteins (6-7).
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Figure 1.A Summary of Proteomic Strategies.
102

Appendix B (Continued)
B.1 References for Appendix B
1. Xiao, Recker and Deng. “Recent Advances of Proteomics and Cancer Biomarker
Discovery.” Clinical Medicine: Oncology Issue 2 (2008): pages 63-72.
2. Caprioli, Farmer and Gile. “Molecular imaging of biochemical samples: localization of
peptides and proteins using MALDI-TOF MS.” Analytical Chemistry Volume 69 Issue
23 (1997): pages 4751-4760.
3. Adams, Davis, Cazares, Schellhammer, Lynch, Wright “Identifying the signature
proteins of prostate cancer in seminal plasma by SELDI affinity mass spectrometry
(Abstract).” Procession of the America Cancer Research Issue 41 (2000): page 564.
4. Agnetti, Kane, Guarnieri, Caldarera and Van Eyk. “Proteomic technologies in the
study of kinases: novel tools for the investigation of PKC in the heart.”
Pharmacological Research Volume 55 Issue 6 (2007): pages 511–22.
5. Ong, Blagoev, Kratchmarova, Kristensen, Steen, Pandey and Mann. ”Stable isotope
labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to
expression proteomics.” Molecular and Cellular Proteomics Volume 1. Issue 5
(2002): pages 376–386.
6. Griffin, Xie, Bandhakavi, Popko, Mohan, Carlis andHiggins. “iTRAQ reagent-based
quantitative proteomic analysis on a linear ion trap mass spectrometer.” Journal of
Proteome Research Volume 6. Issue 11 (2007): pages 4200-4290.
7. Ross, Huang, Marchese, Williamson, Parker, Hattan, Khainovski, Pillai, Dey and
Daniels. “Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using
Amine-reactive Isobaric Tagging Reagents. Molecular and Cellular Proteomics Issue
3 (2004): pages 1154–69.

103

Appendix C

Contact Angle Measurements

Table 1.A Contact Angle: Amine-Crosslinking to Immobilize Protein A/G.
3-APTMS

avg
ODMS

avg
3-APTMS

GA

avg
Chlorosilane, GA

avg

3-APTMS, GA, A/G

avg
Chlorosilane, GA, AG

Avg

Left
Contact

Right
Contact

Average

16.8

29.1

23.0

9.0

1.9

48.8

69.5

26.0

25.7

25.9

8.2

2.0

43.6

61.5

36.1

24.2

30.1

7.0

1.5

26.7

43.9

26.3
Left
Contact

26.4
Right
Contact

26.3

8.1

1.8

39.7

58.3

100.6

100.5

100.5

2.3

1.3

4.0

9.6

100.0

99.9

100.0

1.9

1.1

2.1

6.4

101.2

101.1

101.1

2.4

1.4

4.5

10.5

100.6

100.5

100.5

2.2

1.3

3.5

8.8

Left
Contact
44.2
46.7
46.4
45.7
45.8
Left
Contact
87.3
82.7
85.3

Right
Contact
44.2
47.4
46.0
46.3
46.0
Right
Contact
88.0
81.9
83.1

Average

Length

Height

Volume

84.2
84.9
Left
Contact
35.8
35.7
32.0
61.3
41.2
Left
Contact
85.0
87.1
75.5
78.9
81.6

Average

44.2
47.1
46.2
46.0
45.9
Average

Length

Length

3.6
3.4
3.5
3.6
3.5
Length

Height

Height

0.7
0.7
0.7
0.8
0.7
Height

Volume

Volume

3.8
4.2
3.7
4.2
4.0
Volume

Area

Area

Area
11.6
11.8
11.2
12.1
11.7
Area

87.6
82.3
84.2

2.8
2.8
2.8

1.3
1.2
1.2

5.1
4.6
4.8

11.4
10.6
11.0

83.8

84.0

2.8

1.2

4.7

10.8

84.2

84.5

2.8

1.2

4.8

11.0

Right
Contact
37.0
36.5
35.9
36.4
36.5
Right
Contact
84.3
86.5
73.9
77.2
80.5

Average
36.4
36.1
33.9
38.9
36.3
Average
84.6
86.8
74.7
78.1
81.0
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Length
3.8
3.4
3.7
3.0
3.5
Length
2.6
2.5
2.8
2.7
2.6

Height
0.6
0.6
0.6
0.5
0.6
Height
1.1
1.2
1.0
1.0
1.1

Volume
3.7
3.2
10.7
4.5
5.5
Volume
3.7
3.8
3.9
3.6
3.8

Area
12.9
11.2
22.9
11.1
14.5
Area
9.3
9.3
9.8
9.2
9.4
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Table 1.B Contact Angle: PEGylation Coverage on the Substrates.
3-APTMS, GA, A/G
BS(peg)

avg
Chlorosilane, A/G
BS(peg)

avg
3-APTMS, GA, A/G
MS(peg)

avg
Chlorosilane, A/G
MS(peg)

avg

Left
Contact
30.3
23.5
18.8
25.2
29.1
25.4
Left
Contact

Right
Contact
28.7
23.3
19.4
27.2
28.6
25.4
Right
Contact

78.3
63.8
84.3
81.5
77.0

77.0
77.3
83.4
82.2
80.0

Left
Contact

69.4
56.5
51.8
50.3
57.0
Left
Contact

69.9
69.7
69.3
66.5
68.8

Right
Contact

68.0
62.9
53.9
48.9
58.4
Right
Contact

69.9
68.3
69.1
68.4
68.9

Average
29.5
23.4
19.1
26.2
28.9
25.4
Average
77.7
70.6
83.9
81.8
78.5
Average
68.7
59.7
52.8
49.6
57.7
Average
69.9
69.0
69.2
67.4
68.9
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Length
4.3
4.9
4.9
4.1
3.8
4.4
Length
3.1
3.2
2.9
3.0
3.0
Length
2.8
3.2
3.1
3.3
3.1
Length
3.1
3.0
3.0
3.0
3.0

Height
0.6
0.5
0.4
0.4
0.5
0.5
Height
1.2
1.3
1.3
1.2
1.2
Height
0.9
1.0
0.8
0.8
0.9
Height
1.0
1.0
1.0
1.0
1.0

Volume
6.3
4.7
4.0
3.4
3.4
4.4
Volume
5.3
5.9
5.3
5.4
5.5
Volume
3.4
5.4
5.3
4.8
4.7
Volume
4.4
4.1
4.1
4.1
4.2

Area
18.7
19.9
19.9
14.8
13.4
17.4
Area
11.8
12.7
11.8
11.8
12.0
Area
9.0
12.4
12.5
12.2
11.5
Area
10.8
10.3
10.3
10.4
10.4
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Table 1.B (Continued)
3-APTMS, GA, A/G
Pluronic

avg
Chlorosilane, A/G
Pluronic

avg

Left
Contact

56.6
54.0
56.7
56.0
55.8
Left
Contact

Right
Contact

57.8
53.3
57.4
56.3
56.2
Right
Contact

Average
57.2
53.6
57.0
56.2
56.0
Average

Length
2.6
2.8
2.6
2.6
2.7
Length

Height
0.7
0.7
0.7
0.7
0.7
Height

Volume
2.8
2.5
2.5
2.0
2.4
Volume

Area
8.1
8.1
7.6
6.8
7.7
Area

63.0
62.2
58.5
61.4

61.0
63.0
57.1
60.6

62.0
62.6
57.8
61.0

2.8
2.9
3.1
2.7

0.8
0.9
0.8
0.8

3.3
3.5
4.2
2.6

9.0
9.4
10.8
7.8

61.3

60.4

60.9

2.9

0.8

3.4

9.3
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Selected ELISA Readings

Table 1.C ELISA Readings for all 5 Substrates. (Note: corresponds to figure 4.4)
with
bcl2

avg
std.
Without
bcl2

avg
std.

1

2

3

4

5

control

0.87

0.27

0.19

0.16

0.23

0.05

0.24

0.66

0.18

0.16

0.41

0.05

0.71

0.23

0.21

0.20

0.28

0.05

0.61

0.39

0.19

0.18

0.31

0.05

0.33

0.24

0.02

0.02

0.09

0.00

1

2

3

4

5

control

0.97

0.34

0.15

0.21

0.25

0.06

0.38

0.27

0.13

0.21

0.11

0.06

0.41

0.55

0.20

0.26

0.15

0.05

0.59

0.39

0.16

0.23

0.17

0.06

0.33

0.14

0.04

0.03

0.06

0.00

Table 1.D ELISA Readings for Antibody Orientation on Substrates 1 and 5.
(Note: data corresponds with figures 4.6 and 4.7).
Substrate 5a
+bcl2
-bcl2
0.46
0.25
0.29
0.21
0.29
0.24
0.28
0.23
avg
0.33
0.23
std
0.09
0.02
Substrate

avg
std

+bcl2
0.46
0.46
0.53
0.36
0.45
0.07

1a
-bcl2
0.46
0.48
0.39
0.16
0.37
0.15

Substrate

+bcl2
0.35
0.31
0.33
0.35
0.33
0.02

1b
-bcl2
0.31
0.28
0.30
0.29
0.29
0.02
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Substrate 5b
bcl2
-bcl2
0.26
0.16
0.20
0.33
0.20
0.25
0.22
0.33
0.22
0.27
0.03
0.08
Substrate

+bcl2
0.36
0.47
0.95
0.47
0.56
0.26

1c
-bcl2
0.37
0.33
0.49
0.44
0.41
0.07

Substrate

+bcl2
0.33
0.38
0.16
0.27
0.28
0.10

e1d
-bcl2
0.34
0.28
0.13
0.18
0.23
0.10
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Table 1.E ELISA Reading Assessing Assembly of Substrate 5.
(Note: data corresponds with figure 4.9).

With
BCL-2

avg
std
Without
BCL-2

avg
std

5a
0.78
1.55
1.04
0.78
1.04
0.36
0.42
0.43
0.65
0.70
0.55
0.14

avg
std

5b
1.63
2.04
1.22
1.09
1.49
0.43

avg
std

0.57
1.51
1.28
1.53
1.22
0.45

avg
std

5c
0.54
0.56
0.64
0.87
0.65
0.15

avg
std

0.44
0.38
0.48
0.74
0.51
0.16
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avg
std

5d
0.80
0.81
0.72
0.80
0.78
0.04

avg
std

0.29
0.70
0.49
0.56
0.51
0.17

